CN104530014B - Sulfamide compound of the dihydrobenzo of 2 oxo 1,2 [cd] indoles 6 and combinations thereof and application - Google Patents
Sulfamide compound of the dihydrobenzo of 2 oxo 1,2 [cd] indoles 6 and combinations thereof and application Download PDFInfo
- Publication number
- CN104530014B CN104530014B CN201410821535.5A CN201410821535A CN104530014B CN 104530014 B CN104530014 B CN 104530014B CN 201410821535 A CN201410821535 A CN 201410821535A CN 104530014 B CN104530014 B CN 104530014B
- Authority
- CN
- China
- Prior art keywords
- indoles
- oxo
- ethyl
- dihydrobenzos
- sulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Sulfamide compound Chemical class 0.000 title claims abstract description 53
- 150000002475 indoles Chemical class 0.000 title claims description 162
- 150000001875 compounds Chemical class 0.000 claims abstract description 72
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 13
- 239000003112 inhibitor Substances 0.000 claims abstract description 10
- 230000004048 modification Effects 0.000 claims abstract description 10
- 238000012986 modification Methods 0.000 claims abstract description 10
- 229940124530 sulfonamide Drugs 0.000 claims description 123
- 238000006467 substitution reaction Methods 0.000 claims description 53
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 40
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 22
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 15
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims description 14
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 9
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 8
- 239000005711 Benzoic acid Substances 0.000 claims description 7
- 235000010233 benzoic acid Nutrition 0.000 claims description 7
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 claims description 7
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 claims description 6
- 125000005605 benzo group Chemical group 0.000 claims description 6
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims description 6
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 241000255964 Pieridae Species 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 150000002240 furans Chemical class 0.000 claims description 5
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims description 5
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 claims description 5
- JXOVTPNBOKLRHT-UHFFFAOYSA-N 3,5-dimethyl-4,5-dihydro-1,2-oxazole Chemical class CC1CC(C)=NO1 JXOVTPNBOKLRHT-UHFFFAOYSA-N 0.000 claims description 4
- 208000009386 Experimental Arthritis Diseases 0.000 claims description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 claims description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
- 201000002491 encephalomyelitis Diseases 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 150000003053 piperidines Chemical class 0.000 claims description 4
- 235000019260 propionic acid Nutrition 0.000 claims description 4
- 201000003068 rheumatic fever Diseases 0.000 claims description 4
- VQKFNUFAXTZWDK-UHFFFAOYSA-N 2-Methylfuran Chemical compound CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 claims description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- UTCMYCAFVUUNBK-UHFFFAOYSA-N benzo[cd]indole Chemical class C1=CC(C=N2)=C3C2=CC=CC3=C1 UTCMYCAFVUUNBK-UHFFFAOYSA-N 0.000 claims description 3
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 claims description 3
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical group CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 claims description 3
- UEMGWPRHOOEKTA-UHFFFAOYSA-N 1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1 UEMGWPRHOOEKTA-UHFFFAOYSA-N 0.000 claims description 2
- OHGRDCDSBYWPEL-UHFFFAOYSA-N 1-fluoroindole Chemical class C1=CC=C2N(F)C=CC2=C1 OHGRDCDSBYWPEL-UHFFFAOYSA-N 0.000 claims description 2
- FZMXBWXWQILZPU-UHFFFAOYSA-N 1-methyl-5-(trifluoromethyl)benzimidazole Chemical class FC(F)(F)C1=CC=C2N(C)C=NC2=C1 FZMXBWXWQILZPU-UHFFFAOYSA-N 0.000 claims description 2
- SIJBDWPVNAYVGY-UHFFFAOYSA-N 2,2-dimethyl-1,3-dioxolane Chemical class CC1(C)OCCO1 SIJBDWPVNAYVGY-UHFFFAOYSA-N 0.000 claims description 2
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 claims description 2
- 125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- PTORRJRYAPMYHC-UHFFFAOYSA-N 3-propan-2-yl-4,5-dihydro-1,2-oxazole Chemical class CC(C)C1=NOCC1 PTORRJRYAPMYHC-UHFFFAOYSA-N 0.000 claims description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- PMZBHPUNQNKBOA-UHFFFAOYSA-N 5-methylbenzene-1,3-dicarboxylic acid Chemical compound CC1=CC(C(O)=O)=CC(C(O)=O)=C1 PMZBHPUNQNKBOA-UHFFFAOYSA-N 0.000 claims description 2
- UUCUQJHYUPXDHN-UHFFFAOYSA-N N-Acetylindole Chemical compound C1=CC=C2N(C(=O)C)C=CC2=C1 UUCUQJHYUPXDHN-UHFFFAOYSA-N 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 2
- 229940095102 methyl benzoate Drugs 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 150000003235 pyrrolidines Chemical class 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 claims 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims 1
- 238000002288 cocrystallisation Methods 0.000 abstract description 5
- 239000012453 solvate Substances 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 4
- 239000000651 prodrug Substances 0.000 abstract description 4
- 229940002612 prodrug Drugs 0.000 abstract description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 abstract description 3
- 230000001900 immune effect Effects 0.000 abstract description 3
- 229930002330 retinoic acid Natural products 0.000 abstract description 3
- 208000026278 immune system disease Diseases 0.000 abstract description 2
- 108090000629 orphan nuclear receptors Proteins 0.000 abstract description 2
- 102000004164 orphan nuclear receptors Human genes 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 229940088592 immunologic factor Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 91
- 238000010189 synthetic method Methods 0.000 description 89
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 84
- 102000005962 receptors Human genes 0.000 description 51
- 108020003175 receptors Proteins 0.000 description 51
- 239000002585 base Substances 0.000 description 36
- 235000002639 sodium chloride Nutrition 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000370 acceptor Substances 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000003513 alkali Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 108050003558 Interleukin-17 Proteins 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 125000005936 piperidyl group Chemical group 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 239000008365 aqueous carrier Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- KVHKWAZUPPBMLL-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoro-2-[3-fluoro-4-[4-[[4-(pyridin-4-ylmethyl)piperazin-1-yl]methyl]phenyl]phenyl]propan-2-ol Chemical compound FC1=CC(C(O)(C(F)(F)F)C(F)(F)F)=CC=C1C(C=C1)=CC=C1CN1CCN(CC=2C=CN=CC=2)CC1 KVHKWAZUPPBMLL-UHFFFAOYSA-N 0.000 description 3
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000012097 Lipofectamine 2000 Substances 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 3
- 239000012124 Opti-MEM Substances 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000242739 Renilla Species 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229960005156 digoxin Drugs 0.000 description 3
- MOAVUYWYFFCBNM-PUGKRICDSA-N digoxin(1-) Chemical compound C[C@H]([C@H]([C@H](C1)O)O)O[C@H]1O[C@H]([C@@H](C)O[C@H](C1)O[C@H]([C@@H](C)O[C@H](C2)O[C@@H](CC3)C[C@@H](CC4)[C@@]3(C)[C@@H](C[C@H]([C@]3(C)[C@H](CC5)C([CH-]O6)=CC6=O)O)[C@@H]4[C@]35O)[C@H]2O)[C@H]1O MOAVUYWYFFCBNM-PUGKRICDSA-N 0.000 description 3
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 229940125425 inverse agonist Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 102000006255 nuclear receptors Human genes 0.000 description 3
- 108020004017 nuclear receptors Proteins 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- OFNLCTNTFQJNAT-UHFFFAOYSA-N 1-ethyl-2-oxo-N-(2-oxo-2-pyrrolidin-1-ylethyl)benzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC(N1CCCC1)=O)=CC=C2)=O OFNLCTNTFQJNAT-UHFFFAOYSA-N 0.000 description 2
- GPYLCFQEKPUWLD-UHFFFAOYSA-N 1h-benzo[cd]indol-2-one Chemical compound C1=CC(C(=O)N2)=C3C2=CC=CC3=C1 GPYLCFQEKPUWLD-UHFFFAOYSA-N 0.000 description 2
- CNBCPSZIPVQUHA-UHFFFAOYSA-N 2-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]benzoic acid Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=CC=C1C(O)=O CNBCPSZIPVQUHA-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108091008773 RAR-related orphan receptors γ Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000006274 endogenous ligand Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229950002366 nafoxidine Drugs 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000021003 saturated fats Nutrition 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- MMAIJMWMJMKEPE-UHFFFAOYSA-N (1,3-dioxophenalen-2-yl) 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC(C1=O)C(=O)C2=C3C1=CC=CC3=CC=C2 MMAIJMWMJMKEPE-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- 125000006091 1,3-dioxolane group Chemical class 0.000 description 1
- XGIKILRODBEJIL-UHFFFAOYSA-N 1-(ethylamino)ethanol Chemical compound CCNC(C)O XGIKILRODBEJIL-UHFFFAOYSA-N 0.000 description 1
- QRVNUWSLHXSXMK-UHFFFAOYSA-N 1-[[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]methyl]cyclopentane-1-carboxylic acid Chemical compound CCN1C(=O)c2cccc3c(ccc1c23)S(=O)(=O)NCC1(CCCC1)C(O)=O QRVNUWSLHXSXMK-UHFFFAOYSA-N 0.000 description 1
- BYZKRKXJSNSHEE-UHFFFAOYSA-N 1-ethyl-2-benzo[cd]indolone Chemical compound C1=CC(N(CC)C2=O)=C3C2=CC=CC3=C1 BYZKRKXJSNSHEE-UHFFFAOYSA-N 0.000 description 1
- IIKQWKDJPZHRJE-UHFFFAOYSA-N 1-ethyl-2-oxo-N-(2-pyridinylmethyl)-6-benzo[cd]indolesulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NCC1=CC=CC=N1 IIKQWKDJPZHRJE-UHFFFAOYSA-N 0.000 description 1
- BCFMZQAGHBFDET-UHFFFAOYSA-N 1-ethyl-2-oxo-N-[(3,4,5-trifluorophenyl)methyl]benzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=CC(=C(C(=C1)F)F)F)=CC=C2)=O BCFMZQAGHBFDET-UHFFFAOYSA-N 0.000 description 1
- GCELTFSMFGNKQI-UHFFFAOYSA-N 1-ethyl-2-oxo-N-[(3-propan-2-yl-4,5-dihydro-1,2-oxazol-5-yl)methyl]benzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1CC(=NO1)C(C)C)=CC=C2)=O GCELTFSMFGNKQI-UHFFFAOYSA-N 0.000 description 1
- BYPAKGDAQWDQLM-UHFFFAOYSA-N 1-ethyl-2-oxo-N-[[4-(trifluoromethyl)phenyl]methyl]benzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=CC=C(C=C1)C(F)(F)F)=CC=C2)=O BYPAKGDAQWDQLM-UHFFFAOYSA-N 0.000 description 1
- RIHWZRSLZORHBM-UHFFFAOYSA-N 1-ethyl-2-oxo-n-(3-phenylphenyl)benzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC(C=1)=CC=CC=1C1=CC=CC=C1 RIHWZRSLZORHBM-UHFFFAOYSA-N 0.000 description 1
- YHNPFOVWPDMOEW-UHFFFAOYSA-N 1-ethyl-2-oxobenzo[cd]indole-6-sulfonyl chloride Chemical compound C1=CC(N(CC)C2=O)=C3C2=CC=CC3=C1S(Cl)(=O)=O YHNPFOVWPDMOEW-UHFFFAOYSA-N 0.000 description 1
- WLQWKZZDKDHLLN-UHFFFAOYSA-N 1-ethyl-6-[4-(pyridin-2-ylmethyl)piperazin-1-yl]sulfonylbenzo[cd]indol-2-one Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)N1CCN(CC1)CC1=NC=CC=C1)=CC=C2)=O WLQWKZZDKDHLLN-UHFFFAOYSA-N 0.000 description 1
- UCLROWGKLQFBAY-UHFFFAOYSA-N 1-ethyl-6-[4-(pyridin-4-ylmethyl)piperazin-1-yl]sulfonylbenzo[cd]indol-2-one Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)N1CCN(CC1)CC1=CC=NC=C1)=CC=C2)=O UCLROWGKLQFBAY-UHFFFAOYSA-N 0.000 description 1
- UVHFKRSIBZJWTD-UHFFFAOYSA-N 1-ethyl-N-(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonyl-N-(5-fluoro-2-methylphenyl)-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)N(C1=C(C=CC(=C1)F)C)S(=O)(=O)C=1C=3C4=C(C(N(C4=CC=1)CC)=O)C=CC=3)=CC=C2)=O UVHFKRSIBZJWTD-UHFFFAOYSA-N 0.000 description 1
- OFPBMSSGXBNKHP-UHFFFAOYSA-N 1-ethyl-N-(2-ethylsulfonylethyl)-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCCS(=O)(=O)CC)=CC=C2)=O OFPBMSSGXBNKHP-UHFFFAOYSA-N 0.000 description 1
- PUCXXOXGVULFAP-UHFFFAOYSA-N 1-ethyl-N-(3-methyl-1-pyridin-3-ylbutyl)-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NC(CC(C)C)C=1C=NC=CC=1)=CC=C2)=O PUCXXOXGVULFAP-UHFFFAOYSA-N 0.000 description 1
- RITCINXEOONILY-UHFFFAOYSA-N 1-ethyl-N-[(2-fluorophenyl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound CCN1C(=O)c2cccc3c(ccc1c23)S(=O)(=O)NCc1ccccc1F RITCINXEOONILY-UHFFFAOYSA-N 0.000 description 1
- QUFOSUFJVBJBLG-UHFFFAOYSA-N 1-ethyl-N-[(2-methylphenyl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=C(C=CC=C1)C)=CC=C2)=O QUFOSUFJVBJBLG-UHFFFAOYSA-N 0.000 description 1
- KFUPUVMAFVQHOT-UHFFFAOYSA-N 1-ethyl-N-[(3-fluoro-4-methylphenyl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=CC(=C(C=C1)C)F)=CC=C2)=O KFUPUVMAFVQHOT-UHFFFAOYSA-N 0.000 description 1
- YWWKBODHMUQASX-UHFFFAOYSA-N 1-ethyl-N-[(3-methylphenyl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=CC(=CC=C1)C)=CC=C2)=O YWWKBODHMUQASX-UHFFFAOYSA-N 0.000 description 1
- HBEIJBBCVOWKHQ-UHFFFAOYSA-N 1-ethyl-N-[(4-fluorophenyl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=CC=C(C=C1)F)=CC=C2)=O HBEIJBBCVOWKHQ-UHFFFAOYSA-N 0.000 description 1
- NSLJOFXJVMOZGY-UHFFFAOYSA-N 1-ethyl-N-[(4-methylmorpholin-2-yl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1CN(CCO1)C)=CC=C2)=O NSLJOFXJVMOZGY-UHFFFAOYSA-N 0.000 description 1
- CHTKQKSSDOCRRB-UHFFFAOYSA-N 1-ethyl-N-[(4-methylphenyl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=CC=C(C=C1)C)=CC=C2)=O CHTKQKSSDOCRRB-UHFFFAOYSA-N 0.000 description 1
- WAZATKBOLMGOEL-UHFFFAOYSA-N 1-ethyl-N-[2-(4-fluorophenyl)ethyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCCC1=CC=C(C=C1)F)=CC=C2)=O WAZATKBOLMGOEL-UHFFFAOYSA-N 0.000 description 1
- MOSVYFYSQBDGJR-UHFFFAOYSA-N 1-ethyl-N-[3-(4-morpholinyl)propyl]-2-oxo-6-benzo[cd]indolesulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NCCCN1CCOCC1 MOSVYFYSQBDGJR-UHFFFAOYSA-N 0.000 description 1
- BQEJBPVZVKZEHL-UHFFFAOYSA-N 1-ethyl-N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=CC(=C(C=C1)F)C(F)(F)F)=CC=C2)=O BQEJBPVZVKZEHL-UHFFFAOYSA-N 0.000 description 1
- YPMVZDYQGAKLGQ-UHFFFAOYSA-N 1-ethyl-N-isoquinolin-7-yl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NC1=CC=C3C=CN=CC3=C1)=CC=C2)=O YPMVZDYQGAKLGQ-UHFFFAOYSA-N 0.000 description 1
- DWAFHBUBFQTYQY-UHFFFAOYSA-N 1-ethyl-n-(2-morpholin-4-ylethyl)-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NCCN1CCOCC1 DWAFHBUBFQTYQY-UHFFFAOYSA-N 0.000 description 1
- NAZKAVKQESNSNR-UHFFFAOYSA-N 1-ethyl-n-(3-methoxyphenyl)-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=CC(OC)=C1 NAZKAVKQESNSNR-UHFFFAOYSA-N 0.000 description 1
- SUFMFRWLORNKTP-UHFFFAOYSA-N 1-ethyl-n-(4-fluorophenyl)-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=C(F)C=C1 SUFMFRWLORNKTP-UHFFFAOYSA-N 0.000 description 1
- YCOXQYUSYKAHEG-UHFFFAOYSA-N 1-ethyl-n-(4-morpholin-4-ylphenyl)-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC(C=C1)=CC=C1N1CCOCC1 YCOXQYUSYKAHEG-UHFFFAOYSA-N 0.000 description 1
- ZAFDZZBLLWYWKW-UHFFFAOYSA-N 1-ethyl-n-[(4-methoxyphenyl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NCC1=CC=C(OC)C=C1 ZAFDZZBLLWYWKW-UHFFFAOYSA-N 0.000 description 1
- SCLDISKZJONBTM-UHFFFAOYSA-N 1-ethyl-n-[(5-fluoro-1h-indol-2-yl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound FC1=CC=C2NC(CNS(=O)(=O)C3=C4C=CC=C5C(=O)N(C(C=C3)=C54)CC)=CC2=C1 SCLDISKZJONBTM-UHFFFAOYSA-N 0.000 description 1
- XZLRBEJBFPODQF-UHFFFAOYSA-N 1-ethyl-n-[(5-methoxy-1h-indol-2-yl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound COC1=CC=C2NC(CNS(=O)(=O)C3=C4C=CC=C5C(=O)N(C(C=C3)=C54)CC)=CC2=C1 XZLRBEJBFPODQF-UHFFFAOYSA-N 0.000 description 1
- FLEGYXZFZBOCSJ-UHFFFAOYSA-N 1-ethyl-n-[(5-methyl-2h-indazol-3-yl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=C(C)C=C2C(CNS(=O)(=O)C3=C4C=CC=C5C(=O)N(C(C=C3)=C54)CC)=NNC2=C1 FLEGYXZFZBOCSJ-UHFFFAOYSA-N 0.000 description 1
- LVBJVCATWRVLGO-UHFFFAOYSA-N 1-ethyl-n-[[1-methyl-5-(trifluoromethyl)benzimidazol-2-yl]methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound FC(F)(F)C1=CC=C2N(C)C(CNS(=O)(=O)C3=C4C=CC=C5C(=O)N(C(C=C3)=C54)CC)=NC2=C1 LVBJVCATWRVLGO-UHFFFAOYSA-N 0.000 description 1
- GNUSAABXOXWQNT-UHFFFAOYSA-N 1-ethyl-n-[[4-methyl-6-(trifluoromethyl)pyrimidin-2-yl]methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NCC1=NC(C)=CC(C(F)(F)F)=N1 GNUSAABXOXWQNT-UHFFFAOYSA-N 0.000 description 1
- WRWPPGUCZBJXKX-UHFFFAOYSA-N 1-fluoro-4-methylbenzene Chemical compound CC1=CC=C(F)C=C1 WRWPPGUCZBJXKX-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- WGSSQBRNCISLKY-UHFFFAOYSA-N 2-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]-3-(furan-2-yl)propanoic acid Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NC(C(=O)O)CC=1OC=CC=1)=CC=C2)=O WGSSQBRNCISLKY-UHFFFAOYSA-N 0.000 description 1
- NBEJNEYJRHATSF-UHFFFAOYSA-N 2-[[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]methyl]benzoic acid Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=C(C(=O)O)C=CC=C1)=CC=C2)=O NBEJNEYJRHATSF-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical class ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- OATZWNYZMHFZHU-UHFFFAOYSA-N 2-ethyl-2-[[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]methyl]butanoic acid Chemical compound C(C)C(C(=O)O)(CC)CNS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 OATZWNYZMHFZHU-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
- IGQSEUSWXCUCSY-UHFFFAOYSA-N 3-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]-3-(5-methylfuran-2-yl)propanoic acid Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NC(CC(=O)O)C=1OC(=CC=1)C)=CC=C2)=O IGQSEUSWXCUCSY-UHFFFAOYSA-N 0.000 description 1
- QAIQQAXISBNHPL-UHFFFAOYSA-N 3-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]heptanoic acid Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NC(CC(=O)O)CCCC)=CC=C2)=O QAIQQAXISBNHPL-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- BQVLDLQFZWVOEA-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-3-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]butanoic acid Chemical compound CC=1C=C(C=C(C=1)C)CC(CC(=O)O)NS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 BQVLDLQFZWVOEA-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- ZWXIXHAKODDHHY-UHFFFAOYSA-N 4-methyl-6-(trifluoromethyl)pyrimidine Chemical class CC1=CC(C(F)(F)F)=NC=N1 ZWXIXHAKODDHHY-UHFFFAOYSA-N 0.000 description 1
- TWNLPJUZPPUEIW-UHFFFAOYSA-N 5-[[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]methyl]thiophene-2-carboxylic acid Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=CC=C(S1)C(=O)O)=CC=C2)=O TWNLPJUZPPUEIW-UHFFFAOYSA-N 0.000 description 1
- MXDXAFAFEXUPIX-UHFFFAOYSA-N 6-[4-(2-chlorophenyl)piperazin-1-yl]sulfonyl-1-ethylbenzo[cd]indol-2-one Chemical compound ClC1=C(C=CC=C1)N1CCN(CC1)S(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 MXDXAFAFEXUPIX-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241001044369 Amphion Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- KURGRPNQBJPBJD-UHFFFAOYSA-N C(C)(=O)C1(CCCCC1)NS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 Chemical compound C(C)(=O)C1(CCCCC1)NS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 KURGRPNQBJPBJD-UHFFFAOYSA-N 0.000 description 1
- AADSJPKBOIGAAW-CYYJNZCTSA-N C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC(C=C1)=CC=C1\N=N\C1=CC=CC=C1 Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC(C=C1)=CC=C1\N=N\C1=CC=CC=C1 AADSJPKBOIGAAW-CYYJNZCTSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- BGRBFBXCSBWJHJ-UHFFFAOYSA-N N-(1,3-benzodioxol-5-ylmethyl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound O1COC2=C1C=CC(=C2)CNS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 BGRBFBXCSBWJHJ-UHFFFAOYSA-N 0.000 description 1
- XVCAKXWYYQVMQC-UHFFFAOYSA-N N-(2,4-difluorophenyl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound FC1=C(C=CC(=C1)F)NS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 XVCAKXWYYQVMQC-UHFFFAOYSA-N 0.000 description 1
- LLUXHQYYAQRGKI-UHFFFAOYSA-N N-[(2-chloro-6-fluorophenyl)methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound ClC1=C(CNS(=O)(=O)C=2C=3C4=C(C(N(C4=CC=2)CC)=O)C=CC=3)C(=CC=C1)F LLUXHQYYAQRGKI-UHFFFAOYSA-N 0.000 description 1
- GDVVXKDWNBQOCY-UHFFFAOYSA-N N-[(3,5-dimethyl-4H-1,2-oxazol-5-yl)methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound CCN1C(=O)c2cccc3c(ccc1c23)S(=O)(=O)NCC1(C)CC(C)=NO1 GDVVXKDWNBQOCY-UHFFFAOYSA-N 0.000 description 1
- JMNOKWJDMLLHPS-UHFFFAOYSA-N N-[(4-bromo-2-fluorophenyl)methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound BrC1=CC(=C(CNS(=O)(=O)C=2C=3C4=C(C(N(C4=CC=2)CC)=O)C=CC=3)C=C1)F JMNOKWJDMLLHPS-UHFFFAOYSA-N 0.000 description 1
- ADDPCDZUTDTKNU-UHFFFAOYSA-N N-[(4-tert-butylphenyl)methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)(C)(C)C1=CC=C(CNS(=O)(=O)C=2C=3C4=C(C(N(C4=CC=2)CC)=O)C=CC=3)C=C1 ADDPCDZUTDTKNU-UHFFFAOYSA-N 0.000 description 1
- FWDBJJJADNLPSJ-UHFFFAOYSA-N N-[(6-chloropyridin-3-yl)methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound ClC1=CC=C(C=N1)CNS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 FWDBJJJADNLPSJ-UHFFFAOYSA-N 0.000 description 1
- JUTMNVBZSGSYGG-UHFFFAOYSA-N N-[2-(2-chlorophenyl)ethyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound ClC1=C(CCNS(=O)(=O)C=2C=3C4=C(C(N(C4=CC=2)CC)=O)C=CC=3)C=CC=C1 JUTMNVBZSGSYGG-UHFFFAOYSA-N 0.000 description 1
- IXHXGPOFOGHOGX-UHFFFAOYSA-N N-[2-(3-chlorophenyl)ethyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound ClC=1C=C(CCNS(=O)(=O)C=2C=3C4=C(C(N(C4=CC=2)CC)=O)C=CC=3)C=CC=1 IXHXGPOFOGHOGX-UHFFFAOYSA-N 0.000 description 1
- XVGYCKTYKPEPNJ-UHFFFAOYSA-N N-[2-(4-chlorophenyl)ethyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound ClC1=CC=C(CCNS(=O)(=O)C=2C=3C4=C(C(N(C4=CC=2)CC)=O)C=CC=3)C=C1 XVGYCKTYKPEPNJ-UHFFFAOYSA-N 0.000 description 1
- AZXPDISIFJIKHJ-UHFFFAOYSA-N N-[3-bromo-5-(trifluoromethyl)phenyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound BrC=1C=C(C=C(C=1)C(F)(F)F)NS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 AZXPDISIFJIKHJ-UHFFFAOYSA-N 0.000 description 1
- PWQHOZJOFCEBQC-UHFFFAOYSA-N N-[4-chloro-3-(trifluoromethyl)phenyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound ClC1=C(C=C(C=C1)NS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2)C(F)(F)F PWQHOZJOFCEBQC-UHFFFAOYSA-N 0.000 description 1
- FAALMMNBSWGUEJ-UHFFFAOYSA-N N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound FC(C=1C=C(CNS(=O)(=O)C=2C=3C4=C(C(N(C4=CC=2)CC)=O)C=CC=3)C=C(C=1)C(F)(F)F)(F)F FAALMMNBSWGUEJ-UHFFFAOYSA-N 0.000 description 1
- RSLYPFXUIIJUAK-UHFFFAOYSA-N N-benzhydryl-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1(=CC=CC=C1)C(NS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2)C1=CC=CC=C1 RSLYPFXUIIJUAK-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100023421 Nuclear receptor ROR-gamma Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003110 Primojel Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- OZBSSKGBKHOLGA-UHFFFAOYSA-N SR 1001 Chemical compound S1C(NC(=O)C)=NC(C)=C1S(=O)(=O)NC1=CC=C(C(O)(C(F)(F)F)C(F)(F)F)C=C1 OZBSSKGBKHOLGA-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000003016 alphascreen Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- QNEFNFIKZWUAEQ-UHFFFAOYSA-N carbonic acid;potassium Chemical compound [K].OC(O)=O QNEFNFIKZWUAEQ-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- BXBSSGWGYRFAEK-UHFFFAOYSA-N ethyl 1-[[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]methyl]cyclopentane-1-carboxylate Chemical compound C(C)OC(=O)C1(CCCC1)CNS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 BXBSSGWGYRFAEK-UHFFFAOYSA-N 0.000 description 1
- PMMZFMFPBNVKBE-UHFFFAOYSA-N ethyl 2-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]-3-(furan-2-yl)propanoate Chemical compound CCOC(=O)C(Cc1ccco1)NS(=O)(=O)c1ccc2N(CC)C(=O)c3cccc1c23 PMMZFMFPBNVKBE-UHFFFAOYSA-N 0.000 description 1
- DEBNNXJSFGNBMW-UHFFFAOYSA-N ethyl 2-[[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]methyl]benzoate Chemical compound CCOC(=O)c1ccccc1CNS(=O)(=O)c1ccc2N(CC)C(=O)c3cccc1c23 DEBNNXJSFGNBMW-UHFFFAOYSA-N 0.000 description 1
- RJYCJKKLHHBJJU-UHFFFAOYSA-N ethyl 3-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]-3-(5-methylfuran-2-yl)propanoate Chemical compound CCOC(=O)CC(NS(=O)(=O)c1ccc2N(CC)C(=O)c3cccc1c23)c1ccc(C)o1 RJYCJKKLHHBJJU-UHFFFAOYSA-N 0.000 description 1
- OGBVCIBUNUBGAF-UHFFFAOYSA-N ethyl 4-(3,5-dimethylphenyl)-3-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]butanoate Chemical compound CCOC(=O)CC(Cc1cc(C)cc(C)c1)NS(=O)(=O)c1ccc2N(CC)C(=O)c3cccc1c23 OGBVCIBUNUBGAF-UHFFFAOYSA-N 0.000 description 1
- UGGCDUDPDNFZOD-UHFFFAOYSA-N ethyl 5-[[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]methyl]thiophene-2-carboxylate Chemical compound CCOC(=O)c1ccc(CNS(=O)(=O)c2ccc3N(CC)C(=O)c4cccc2c34)s1 UGGCDUDPDNFZOD-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- DQOCFCZRZOAIBN-WZHZPDAFSA-L hydroxycobalamin Chemical compound O.[Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O DQOCFCZRZOAIBN-WZHZPDAFSA-L 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 102000004311 liver X receptors Human genes 0.000 description 1
- 108090000865 liver X receptors Proteins 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910000474 mercury oxide Inorganic materials 0.000 description 1
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 1
- 229940100630 metacresol Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- IIHIJFJSXPDTNO-UHFFFAOYSA-N methyl cyclopentanecarboxylate Chemical class COC(=O)C1CCCC1 IIHIJFJSXPDTNO-UHFFFAOYSA-N 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- ZEYXKTVEVPBQEM-UHFFFAOYSA-N n-(1-acetyl-2,3-dihydroindol-5-yl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=C2N(C(C)=O)CCC2=CC(NS(=O)(=O)C2=C3C=CC=C4C(=O)N(C(C=C2)=C43)CC)=C1 ZEYXKTVEVPBQEM-UHFFFAOYSA-N 0.000 description 1
- OCAANUCNWHJWBD-UHFFFAOYSA-N n-(1-acetylpiperidin-4-yl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1CCN(C(C)=O)CC1 OCAANUCNWHJWBD-UHFFFAOYSA-N 0.000 description 1
- GIDFIRMLDHUPHY-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC(CC1)CCN1CC1=CC=CC=C1 GIDFIRMLDHUPHY-UHFFFAOYSA-N 0.000 description 1
- DFBIMODMIYPVEE-UHFFFAOYSA-N n-(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonyl-n-(4-methoxyphenyl)pyridine-4-carboxamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)N(C=1C=CC(OC)=CC=1)C(=O)C1=CC=NC=C1 DFBIMODMIYPVEE-UHFFFAOYSA-N 0.000 description 1
- QHDVAJSQYPJXAT-UHFFFAOYSA-N n-(2-acetylphenyl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=CC=C1C(C)=O QHDVAJSQYPJXAT-UHFFFAOYSA-N 0.000 description 1
- ISFQOKXXKVBMFZ-UHFFFAOYSA-N n-(2-benzoylphenyl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=CC=C1C(=O)C1=CC=CC=C1 ISFQOKXXKVBMFZ-UHFFFAOYSA-N 0.000 description 1
- JZFPQXYCIYFFCS-UHFFFAOYSA-N n-(2-tert-butylphenyl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=CC=C1C(C)(C)C JZFPQXYCIYFFCS-UHFFFAOYSA-N 0.000 description 1
- CSCNKXNQAPIIDE-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=C(OC)C(OC)=C1 CSCNKXNQAPIIDE-UHFFFAOYSA-N 0.000 description 1
- GUQFBNIBOLNMAM-UHFFFAOYSA-N n-(3-acetylphenyl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=CC(C(C)=O)=C1 GUQFBNIBOLNMAM-UHFFFAOYSA-N 0.000 description 1
- FBJRRYCFCNCYHU-UHFFFAOYSA-N n-(3-tert-butylphenyl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=CC(C(C)(C)C)=C1 FBJRRYCFCNCYHU-UHFFFAOYSA-N 0.000 description 1
- TWOOVCPUMKWXNA-UHFFFAOYSA-N n-(4-acetylphenyl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=C(C(C)=O)C=C1 TWOOVCPUMKWXNA-UHFFFAOYSA-N 0.000 description 1
- DRBVUHJDRZINML-UHFFFAOYSA-N n-[(1-acetylpiperidin-4-yl)methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NCC1CCN(C(C)=O)CC1 DRBVUHJDRZINML-UHFFFAOYSA-N 0.000 description 1
- ZTUTWOVXSWGGSQ-UHFFFAOYSA-N n-[(2,5-dichlorophenyl)methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NCC1=CC(Cl)=CC=C1Cl ZTUTWOVXSWGGSQ-UHFFFAOYSA-N 0.000 description 1
- YFMAKAHUXUDKSK-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NCC1=CC=CC=C1Cl YFMAKAHUXUDKSK-UHFFFAOYSA-N 0.000 description 1
- SXKUBJSGXSLHDC-UHFFFAOYSA-N n-[(3-chloro-4-fluorophenyl)methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NCC1=CC=C(F)C(Cl)=C1 SXKUBJSGXSLHDC-UHFFFAOYSA-N 0.000 description 1
- HQYQJCSODDOMTE-UHFFFAOYSA-N n-[4-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]phenyl]acetamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=C(NC(C)=O)C=C1 HQYQJCSODDOMTE-UHFFFAOYSA-N 0.000 description 1
- FOUVRVROXNFCJM-UHFFFAOYSA-N n-cyclopentyl-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1CCCC1 FOUVRVROXNFCJM-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000009719 polyimide resin Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- OSEKJLPRHACLQL-UHFFFAOYSA-N tert-butyl n-[3-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]phenyl]carbamate Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=CC(NC(=O)OC(C)(C)C)=C1 OSEKJLPRHACLQL-UHFFFAOYSA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
- C07D209/92—Naphthostyrils
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention relates to a kind of sulfamide compound of 2 oxo 1,2 dihydrobenzo [cd] indoles 6 and combinations thereof and application.The invention provides the compound with the architectural feature of formula I as new vitamin A acid orphan nuclear receptor γ hypotypes (ROR γ) inhibitor, and the application of such compound and its pharmaceutically acceptable salt, isomers, racemic modification, pro-drug cocrystallization compound, hydrate, solvate in the medicine for treating or preventing the gamma regulated relevant diseases of ROR.Importantly, this kind of compound is probably used for the generation for reducing the immune factor related to immunological diseases and mitigates the generation of the symptom and cancer of immunologic derangement.
Description
Technical field
The invention belongs to technical field of chemical medicine, more particularly to a kind of 2- oxos -1,2- dihydrobenzo [cd] indoles -
6- sulfonic acid amide derivatives and its pharmaceutically acceptable salt or stereoisomer and its prodrugs and preparation method, and should
Class compound is preparing treatment by the application in the medicine of immune related diseases gamma regulated ROR.
Background technology
Retinoic acid-related orphan nuclear receptor (ROR) is one of member of nuclear receptor family, it can regulate and control a variety of physiology and
Biochemical process.ROR families include three types ROR α, ROR β, and ROR γ.Three kinds of different ROR can be in different tissues
It is middle to express and regulate and control different physiology courses.ROR α are mainly distributed on liver, skeletal muscle, skin, lung, adipose tissue, kidney,
Thymus gland and brain .ROR β sphere of action very littles, mainly acting on central nervous system .ROR γ can express in many tissues,
Including liver, animal tallow and skeletal muscle.Mammal lacks the phenomenon that ROR γ show blood glucose reduction.
ROR γ have two kinds of hypotypes:ROR γ 1 and ROR γ t (ROR γ 2).ROR γ 1 are in many tissues, such as:Thymus gland, muscle,
Expressed in kidney and liver, and ROR γ t are then only expressed in immunocyte.ROR γ t are believed to modulating T cell auxiliary T
The differentiation of cell 17 (Th17).Th17 is the cell of a kind of helper cell, and this cell can produce interleukin-17 (IL-17)
With other cytohormones.It has been found that Th17 plays the effect of key in the immunological diseases fermentation of mouse, as encephalomyelitis and glue
Former Induced Arthritis.In addition, Th17 have been found to human inflammation's disease and immunologic derangement, e.g., multiple sclerosis, wind
Wet arthritis, psoriasis, clone's disease such as disease and asthma have relation.There is now document report ROR γ may be with prostate
The generation of cancer is relevant with development.
ROR when no endogenous ligands connect also can controlling gene transcription, in the crystal knot of the ligand binding domain to ROR
Find that cholesterol and cholesterol sulfonate can be entered in liganded pockets in structure test.Soon, it is found that some row hydroxyl courages are consolidated
01 derivatives can regulate and control ROR transcriptional activity, however, these cholesterol derivatives whether be ROR endogenous ligands it is also unclear
Chu.And then there are some researches show a kind of small-molecule substance T1317 of synthesis can be combined with ROR γ and ROR α and regulate and control theirs
Activity, but also other nuclear receptors (LXR α/βs, FXR, PXR) have effect to this compound with least four, so as to limit its conduct
Treat the development of immunity disease medicine.Have now been found that a kind of ROR α selective inverse agonist SR3335, to ROR γ and
ROR α have inverse agonist SR1001, the ROR γ of double action selective inverse agonist SR2211 and SR1555, and they are all
The differentiation of IL-17 cell can be suppressed.GlaxoSmithKline PLC company has delivered a series of patents at present, mentions a kind of virtue
Fragrant aminated compounds can suppress ROR acceptors.Also there are article report natural products digoxin and ursolic acid can be as ROR γ's
Selective regulation material and the differentiation that IL-17 cell can be suppressed.But further investigations have shown that digoxin
There is very strong side effect, ursolic acid also has effect to glucocorticoid receptor.These researchs all show to synthesize ROR γ selectivity
Inhibitor has very big potential value as the medicine for suppressing IL-17 expression.
The content of the invention
One of the technical problem to be solved in the invention is to provide a kind of Novel 2-oxo -1,2- dihydrobenzos [cd] Yin
Diindyl -6- sulfamide compounds.
The technical scheme for solving above-mentioned technical problem is as follows:
It is an object of the present invention to provide compound shown in a kind of formula (I), itself or its each optical isomer, using upper
Acceptable cocrystallization compound, hydrate or solvate:
In formula:
R1Optionally certainly:
1)H;
2)C1~C5Alkyl;
3)C3~C6Cycloalkyl;
R2,R3Optionally certainly:
1)H;
2)C0~C4Alkylidene-R4;
3)C0~C4Alkylidene-R5- cycloalkyl;
4)C0~C4Alkylidene-R5- heterocyclic radical;
R described above4Optionally from-OR6、-COR6、-COOR6、-S(O)mR6、-S(O)mR6, wherein m is 0 or 2,
R6Optionally from C1~C3Alkyl;
The R5Optionally from-COR7、-COOR7, wherein R7Optionally from C1~C3Alkylidene;
The cycloalkyl optionally from phenyl, naphthyl, and the cycloalkyl by 0,1,2 or 3 optionally from halogen, methyl, second
Base, propyl group, isopropyl, the tert-butyl group, trifluoromethyl, cyano group, carboxyl, nitro, amino, phenyl-diazenyl ,-CONH2、-
COOR8、-COR8、-OR8、-NHCOR8、-NHCOOR8、-C6H5R9, morpholinyl, piperidyl, tetrahydrofuran base, Pyridyl residues take
Generation, wherein R8Optionally from C1~C4Alkyl, phenyl, R9Optionally from C1~C4Alkyl, halogen, acetyl group, methoxyl group, ethyoxyl;
The heterocyclic radical is optionally from imidazole radicals, triazolyl, pyrazolyl, base, thienyl, oxazolyl, isoxazolyls, the pyrrole of muttering of barking
Piperazine base, pyridazinyl, pyridine radicals, pyrimidine radicals, pyrrole radicals, piperazinyl, nafoxidine base, piperidyl, morpholinyl, 1,3- dioxolanes
Base, isoquinolyl, indoline base, 1H- indazolyls, 1H- benzos [d] imidazole radicals, 1H- indyls, benzo [d] [1,3] dioxa
Cyclopentenyl, benzo [d] thiazolyl, H- pyrazoles -3 (2H) -one base, and the heterocyclic radical can be by 0,1,2 or 3 optionally from halogen
Element, methyl, ethyl, propyl group, isopropyl, the tert-butyl group, trifluoromethyl, cyano group, carboxyl, nitro, amino, phenyl-diazenyl ,-
CONH2、-COOR8、-COR8、-OR8、-NHCOR8、-NHCOOR8、-C6H5R9, morpholinyl, piperidyl, tetrahydrofuran base, pyridine radicals
Group substitutes, wherein R8Optionally from C1~C4Alkyl, phenyl, R9Optionally from C1~C4Alkyl, halogen, acetyl group, methoxyl group, ethoxy
Base;
R2And R3It is asynchronously H.
In one of the embodiments, the R1It is selected from:
1)H;
2) methyl, ethyl, propyl group, isopropyl, the tert-butyl group;
3) cyclopropyl, cyclobutyl, cyclohexyl.
In one of the embodiments, the R2, R3Optionally certainly:
1)C1-C3Alkylidene-R4, R4Optionally from-OR6、-COR6、-COOR6、-S(O)2R6、-S(O)2R6, R6Optionally from hydrogen,
C1~C3Alkyl;
2)C0~C4Alkylidene-R5- cycloalkyl, R5Optionally from-COR7、-COOR7, wherein R7Optionally from C1~C3Alkylidene;
Cycloalkyl is optionally from phenyl, naphthyl, wherein cycloalkyl described above can be by 0,1,2 or 3 optionally from fluorine, chlorine, bromine, fluoroform
Base, carboxyl, phenyl-diazenyl ,-CONH2、-COOR8、-COR8、-OR8、-NHCOR8、-NHCOOR8、-C6H5R9, morpholinyl, piperazine
Piperidinyl, tetrahydrofuran base, Pyridyl residues substitution, wherein R8Optionally from C1~C4 alkyl, phenyl, R9Optionally from methyl, ethyl,
Isopropyl, the tert-butyl group, fluorine, chlorine, bromine, acetyl group, methoxyl group, ethyoxyl;
3)C0~C4Alkylidene-R5- heterocyclic radical, R5Optionally from-COR7、-COOR7, wherein R7Optionally from C1~C3Alkylidene;
Heterocyclic radical optionally from imidazole radicals, pyrazolyl, bark mutter base, thienyl, oxazolyl, isoxazolyls, pyridine radicals, pyrimidine radicals, pyrrole radicals,
Nafoxidine base, piperidyl, morpholinyl, 1,3- dioxolanyls, isoquinolyl, indoline base, 1H- indazolyls, 1H- benzos
[d] imidazole radicals, 1H- indyls, benzo [d] [1,3] dioxa cyclopentenyl, benzo [d] thiazolyl, H- pyrazoles -3 (2H) -one
Base, wherein heterocyclic radical described above can be by 0,1,2 or 3 optionally from fluorine, chlorine, bromine, methyl, ethyl, propyl group, isopropyl, tertiary fourth
Base, trifluoromethyl, carboxyl ,-CONH2、-COOR8、-COR8、-OR8、-NHCOR8、-NHCOOR8、-C6H5R9, morpholinyl, piperidines
Base, tetrahydrofuran base, Pyridyl residues substitution, wherein R8Optionally from C1~C4Alkyl, phenyl, R9Optionally from methyl, ethyl, different
Propyl group, the tert-butyl group, fluorine, chlorine, bromine, acetyl group, methoxyl group, ethyoxyl.
Further, in one of the embodiments, R1It is selected from:
1)H;
2) ethyl;
R2, R3It is selected from:
1)H;
2) phenyl, it can be by 1 or 2 or 3 methoxyl groups, ethyoxyl, formoxyl, the tert-butyl group, morpholinyl, phenyl phenodiazine
Alkenyl, phenoxy group, formamido, t-butyl carbamate substitution;
3) quinoline, isoquinolin, benzothiazole, it optionally can substitute by 0 or 1 ethyoxyl.
It is a further object of the present invention to provide the application of above-claimed cpd.
Concrete technical scheme is as follows:Above-claimed cpd or its pharmaceutically acceptable salt, isomers, racemic modification, precursor
The application of medicine cocrystallization compound, hydrate, solvate in ROR γ acceptor inhibitors are prepared.
Above-claimed cpd or its pharmaceutically acceptable salt, isomers, racemic modification, pro-drug cocrystallization compound,
Hydrate, solvate are preparing treatment encephalomyelitis, Collagen-induced Arthritis, multiple as ROR γ acceptor inhibitors
Sclerosis, rheumatic arthritis, psoriasis, clone's disease, asthma and prostate cancer medicine in application.
It is a further object of the present invention to provide a kind of pharmaceutical composition.
Concrete technical scheme is as follows.
A kind of pharmaceutical composition as ROR γ acceptor inhibitors, its active component include above-claimed cpd or its medicine
Acceptable salt, isomers, racemic modification, pro-drug cocrystallization compound, hydrate, solvate on.
The invention provides 2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamides with Formulas I architectural feature
Compound.It has been investigated that such compound can effectively suppress ROR γ acceptors, so as to regulate and control Th17 differentiation, treatment brain can be used as
Myelitis, Collagen-induced Arthritis, multiple sclerosis, rheumatic arthritis, psoriasis, clone's disease, asthma and forefront
The medicine of the inflammation associated class disease such as gland cancer.
Brief description of the drawings
Fig. 1 illustrate inhibitory activity of the embodiment 1-91 compounds to ROR γ albumen.
Fig. 2 illustrate the embodiment 1-91 compounds inhibitory activity horizontal to ROR gamma cellses.
Embodiment
In chemicals of the present invention, as any variable (such as R1、R2Deng) occur more than once in any component, then
Its definition occurred every time is independently of other definition occurred every time.Equally, it is allowed to the combination of substituent and variable, as long as this
Combination makes compound stable.The line that loop system is included in from substituent represents that signified key may be connected to any annular atom that can substitute
On.If loop system is polycyclic, it means that this key, which is connected only on any appropriate carbon atom of adjacent loops, is appreciated that this
Field those of ordinary skill may be selected the compounds of this invention substituent and substitution pattern and provide chemically stable and can lead to
Cross the compound that the method for art technology and following proposition is readily synthesized from readily available raw material.If instead of base certainly
Body is exceeded a group substitution, it should be understood that these groups can be in identical carbon atoms or on different carbon atoms, as long as making structure
Stable phrases " being optionally substituted by one or more substituents " are considered as " optionally being substituted " phase by least one substituent with phrase
When and preferred embodiment will have 0-3 substituent in the case.
Terms used herein " alkyl " and " alkylidene " mean to include the side chain and straight chain with particular carbon atom number
Saturated fat alkyl.For example, in " C1-C4 " alkyl " C1-C4 " definition include with straight or branched arrangement have 1,2,
3rd, 4, the group of carbon atom.For example, " C1-C4 " alkyl " specifically includes methyl, ethyl, n-propyl, isopropyl, normal-butyl, tertiary fourth
Base, isobutyl group.Term " cycloalkyl " refers to the monocyclic saturated fat alkyl with particular carbon atom number.Such as " cycloalkyl " includes
Cyclopropyl, methyl-cyclopropyl, 2,2- dimethyl-cyclobutyls, 2- ethyI-cyclopentyls, cyclohexyl etc..
Unless otherwise defined, alkyl, cycloalkyl and heterocyclyl substituent can be unsubstituted or substitution.For example,
(C1-C4) alkyl can be selected from OH, halogen, alkoxy, dialkyl amido or heterocyclic radical, such as morpholine by one, two or three
The substituent substitution of base, piperidyl etc..
The present invention includes the free form of type I compound, also including its pharmaceutically acceptable salt and stereoisomer.This
The specific exemplary compounds of some in text are the protonated salt of aminated compounds.Term " free form " refers to non-salt shape
The aminated compounds of formula.The pharmaceutically-acceptable salts being included not only include the exemplary salt of specific compound described herein,
Also the typical pharmaceutically acceptable salt of all type I compound free forms is included.Techniques known in the art separation can be used
The free form of the compound specific salts.For example, can be by using appropriate alkali dilute aqueous solution such as NaOH dilute aqueous solutions, carbonic acid
Potassium dilute aqueous solution, weak aqua ammonia and sodium acid carbonate dilute aqueous solution, which handle the salt, regenerates free form.Free form is in some physics
Property for example in polar solvent each more or less distinguish with its in solubility by salt form, but is this acid of purpose of invention
Each free form is suitable with its in terms of other pharmacy for salt and alkali salt.
It can synthesize the present invention's from containing the compounds of this invention of basic moiety or acidic moiety by conventional chemical processes
Pharmaceutically acceptable salt.Generally, by ion-exchange chromatography or free alkali and stoichiometric amount or the required salt of excess are passed through
The reaction in the combination of appropriate solvent or multi-solvents of the inorganic or organic acid of form prepares the salt of alkali compounds.Similar,
The salt of acid compound is formed by being reacted with appropriate inorganic or organic base.
Therefore, the pharmaceutically acceptable salt of the compounds of this invention is included by alkaline the compounds of this invention and inorganic or have
The conventional non-toxic salts for the compounds of this invention that machine acid reaction is formed.For example, conventional nontoxic salts include deriving from inorganic acid such as salt
The salt of acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid etc., also include from organic acid such as acetic acid, propionic acid, butanedioic acid, second
Alkyd, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, flutter acid, maleic acid, hydroxymaleic acid, phenylacetic acid,
Glutamic acid, benzoic acid, salicylic acid, p-aminobenzene sulfonic acid, the benzoic acid of 2 one acetoxyl group one, fumaric acid, toluenesulfonic acid, methanesulfonic acid,
The salt of the preparations such as ethane disulfonic acid, oxalic acid, isethionic acid, trifluoroacetic acid.
If the compounds of this invention is acid, appropriate " pharmaceutically acceptable salt " refers to by pharmaceutically acceptable
Nontoxic alkali include salt prepared by inorganic base and organic base and derive from the salt of inorganic base including aluminium salt, ammonium salt, calcium salt, mantoquita, iron
Salt, ferrous salt, lithium salts, magnesium salts, manganese salt, manganous salt, sylvite, sodium salt, zinc salt etc..Particularly preferred ammonium salt, calcium salt, magnesium salts, sylvite
And sodium salt.Salt derived from pharmaceutically acceptable organic nontoxic alkali, the alkali includes the salt of primary amine, secondary amine and tertiary amine, substituted
Amine include naturally occurring substitution amine, cyclic amine and deacidite for example arginine, glycine betaine, caffeine, choline,
N, N'- dibenzyl-ethylenediamin, diethylamine, 2- DEAE diethylaminoethanols, DMAE, ethylaminoethanol, monoethanolamine, second
Diamines, N-ethylmorpholine, N-ethylpiperidine, gucosamine, Glucosamine, histidine, hydroxycobalamin, isopropylamine, lysine,
Methyl glucose osamine, morpholine, piperazine, piperidines, croak smack one's lips, more polyimide resins, procaine, purine, theobromine, triethylamine, trimethylamine,
Tripropyl amine (TPA), tromethamine etc..
Because the acidic moiety such as carboxyl of deprotonation in compound in physiological conditions can be anion, and it is this
The electric charge carried then can be by internal protonated or alkylation the basic moiety such as quaternary nitrogen atom with cation
Balance is offset, it is noted that the compounds of this invention is potential inner salt or amphion.
In addition to known in the literature or the illustration in experimental arrangement standard method, it can use as shown in following scheme
Reaction prepare the compounds of this invention.Therefore, following illustrative approach is to be the purpose illustrated without being limited to listed chemical combination
Thing or any specific substituent.The substituent number shown in scheme not necessarily meets number used in claim,
And for clarity, showing monosubstituted base to be connected under the hereinbefore definition of Formulas I allows to have in the compound of multi-substituent.
Scheme
The compound as shown in scheme can be that initiation material is synthesized by the reaction of 5 steps by 1,8- naphthalic anhydrides.
Compound and its pharmaceutically acceptable salt involved by the application can be following for treating according to following method
Disease and the Other diseases do not listed below:1) encephalomyelitis;2) Collagen-induced Arthritis;3) multiple sclerosis;
4) rheumatic arthritis;5) psoriasis;6) disease is cloned;7) asthma;8) prostate cancer.
Further aspect of the present invention provides a kind of pharmaceutical composition, including formula of the present invention (I) compound and it is a kind of or
Several pharmaceutically acceptable auxiliary materials.Composition of the present invention can be liquid, semiliquid or solid form, according to suitable
Prepared in the mode of method of administration used..Compound of the present invention is applicable to various methods of administration when in use, bag
Include but be not limited to following approach, oral, cheek, suction, sublingual, rectum, vagina, it is intracisternal or intrathecal, pass through lumbar puncture, warp
Urethra, through skin or parenteral (including intravenous injection, intramuscular injection, subcutaneous, row intracutaneous injection, intraperitoneal, intrathecal, operation are implanted into)
Deng.
Orally administered composition can be solid, gel or liquid.The example of solid pharmaceutical preparation includes but is not limited to tablet, capsule
Agent, granule and bulk powder.These preparations can selectively contain adhesive, diluent, disintegrant, lubricant, glidant,
Sweetener and flavouring etc..The example of adhesive includes but is not limited to microcrystalline cellulose, glucose solution, mucialga of arabic gummy, bright
Sol solution, sucrose and gelatinized corn starch;The example of lubricant includes but is not limited to talcum, starch, magnesium stearate, calcium stearate, tristearin
Acid;The example of diluent includes but is not limited to lactose, sucrose, starch, mannitol, Dicalcium Phosphate;The example of glidant includes
But it is not limited to silica;The example of disintegrant includes but is not limited to Ac-Di-Sol, primojel, algae
Acid, cornstarch, farina, methylcellulose, agar and carboxymethyl cellulose.
The present composition is given with parenteral, typically based on injection, including subcutaneous, intramuscular or intravenous injection.Note
Any conventionally form can be made into by penetrating agent, such as liquid solution or suspension, be suitable for being dissolved or suspended in liquid before injection
In solid form or emulsion.Example available for the carrier of the pharmaceutical acceptable of injection of the present invention includes but is not limited to
Aqueous carrier, non-aqueous carrier, antimicrobial, isotonic agent, buffer, antioxidant, suspension and dispersant, emulsifying agent, chelating
Agent and other pharmaceutically acceptable materials.The example of aqueous carrier includes sodium chloride injection, woods form parenteral solution, isotonic Portugal
Grape sugar parenteral solution, Sterile Water Injection, glucose and Lactated ringer's injection;The example of non-aqueous carrier comes including plant
Fixing oil, cottonseed oil, corn oil, sesame oil and the peanut oil in source;The example of antimicrobial includes metacresol, benzylalcohol, neoprene
Alcohol, benzalkonium chloride etc.;The example of isotonic agent includes sodium chloride and glucose;Buffer includes phosphate and citrate.
Inventive composition can also be prepared into sterile freeze drying powder injection, and compound is dissolved in into buffer solution of sodium phosphate, its
In containing glucose or other suitable excipient, it is then under standard conditions well known by persons skilled in the art that solution is sterile
Filtering, is followed by freeze-drying, obtains required preparation.
The present invention will be further described for following examples, but the embodiment is not intended to limit the protection model of the present invention
Enclose.
Embodiment 1
1- ethyl-2-oxos-N- (2- oxos -2- (pyrrolidines -1- substitutions) ethyl) -1,2- dihydrobenzos [cd] indoles -
6- sulfonamide (E1)
(1-ethyl-2-oxo-N-(2-oxo-2-(pyrrolidin-1-yl)ethyl)-1,2-dihydrobenzo
[cd]indole-6-sulfonamide)(E1)
Non- that alkene -2- bases 4- toluene sulfonic acide esters of step 1.1,3- dioxo -2,3- dihydros -1H-
(1,3-dioxo-2,3-dihydro-1H-phenalen-2-yl 4-methylbenzenesulfonate)
Added in round-bottomed flask 1,8- naphthalic anhydrides (1-1) (11.9g, 0.06mol), hydroxylamine hydrochloride (4.18g,
0.06mol) with pyridine (70mL), backflow 1 hour is heated to.Be cooled to 80 DEG C, rapidly join 4- toluene sulfochlorides (22.88g,
0.12mol), it is warming up to back flow reaction 1.5 hours.Room temperature is cooled to, mixture is poured into 200g frozen water, stirring has yellow
Precipitation.Stand, filter, washing three times, saturated solution of sodium bicarbonate agitator treating, is filtered, and washing three times, is obtained in 17g
Mesosome 1-2 (78%).
Step 2. benzo [cd] indoles -2 (1H) -one (benzo [cd] indol-2 (1H)-one)
Be separately added into compound 1-2 (17g, 0.048mol) in round-bottomed flask, 50mL ethanol, 40mL water and
2.7mol/L sodium hydroxide solution 60mL, is heated to reflux 3h, cools down and ethanol is removed under reduced pressure, and hydrochloric acid is instilled at 75 DEG C, adjusts
PH to 3 is saved, there is yellow mercury oxide precipitation, is filtered, column chromatography obtains 6.65g yellow solids 1-3 (82%).
MS(ESI),m/z:M+170.0
Step 3.1- ethyls benzo [cd] indoles -2 (1H) -one (1-ethylbenzo [cd] indol-2 (1H)-one)
Compound 1-3 (6.65g, 0.039mol) is added in round-bottomed flask and adds 100mLN, dinethylformamide is made
For solvent, sodium hydride (2.81g, 0.117mol) is added under ice bath, stirs 5min, instills iodopropane (7.33g, 0.047mol),
10min, room temperature reaction, TLC monitoring reactions is added dropwise in low temperature;Water quenching is instilled after question response is complete, under ice bath to go out reaction;With acetic acid second
Ester is extracted three times, merges organic layer, and saturated sodium-chloride water solution is washed once, and anhydrous sodium sulfate drying is overnight, is spin-dried for, and obtains
6.46g yellow solids 1-4 (84%).MS(ESI),m/z:M+198.0
Step 4.1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonic acid chlorides
(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonyl chloride)
By compound 1-4 (6.46g, 0.033mol) by the use of 100mL chloroforms as reaction dissolvent, chlorosulfonic acid is added dropwise under ice bath
(11.5g, 0.099mol), 10min is stirred, be warming up to 50 DEG C, react 6h;Reactant mixture is poured into frozen water, stirred to nothing
Gas escapes, and with dichloromethane aqueous layer extracted three times, merges organic layer, saturated sodium-chloride water solution is washed once, anhydrous sodium sulfate
Dry, column chromatography, obtain 5.75g yellow greenish powder shape solid 1-5 (59%).MS(ESI),m/z:M+297.1
Step 5.1- ethyl-2-oxos-N- (2- oxos-2- (pyrrolidines-1-substitution) ethyl)-1,2- dihydrobenzos [cd]
Indoles -6- sulfonamide (E1)
(1-ethyl-2-oxo-N-(2-oxo-2-(pyrrolidin-1-yl)ethyl)-1,2-dihydrobenzo
[cd]indole-6-sulfonamide)(E1)
1- ethyl-2-oxos -1,2- dihydrobenzo [cd] indoles -6- sulfonic acid chlorides (100mg, 0.34mmol) are dissolved in 10ml
In dichloromethane, add 2- amino -1- (pyrrolidin-1-yl) ethyl ketone (52mg, 0.41mmol) and 2mlDIPEA, room temperature reaction is added dropwise
5h, after reaction completely, washing, dichloromethane is extracted three times, merges organic layer, and saturated sodium-chloride water solution is washed once, anhydrous sulphur
Sour sodium is dried, column chromatography DCM:Methanol=100:1-20:1, obtain 92mg yellow greenish powder shape solids, yield 70%.
1H-NMR (400MHz, d-DMSO) δ 8.70 (d, J=8.4Hz, 1H), 8.13 (d, J=10.8Hz, 1H), 8.07
(d, J=7.6Hz, 1H), 7.96-7.89 (m, 2H), 7.28 (d, J=7.2Hz, 1H), 3.91 (q, J=7.2Hz, 2H)), 3.66
(d, J=5.6Hz, 1H), 3.25 (t, J=6.5Hz, 2H), 3.00 (t, J=6.7Hz, 2H), 1.75-1.72 (m, 2H), 1.62-
1.58 (m, 2H), 1.25 (t, J=6.9Hz, 3H) .MS (ESI), m/z:M+388.0;M-386.0.
Embodiment 2
N- ((1- Acetylpiperidins -4- substitutions) methyl) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulphurs
Acid amides (E2)
(N-((1-acetylpiperidin-4-yl)methyl)-1-ethyl-2-oxo-1,2-dihydrobenzo
[cd]indole-6-sulfonamide)(E2)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.69 (d, J=8.4Hz, 1H), 8.16 (d, J=6.8Hz, 1H), 8.07 (d,
J=7.6Hz, 1H), 7.96 (t, J=7.2Hz, 1H), 7.86 (t, J=6.0Hz, 1H), 7.31 (d, J=7.6Hz, 1H), 4.24
(d, J=8.0Hz, 1H), 3.93 (q, J=6.8Hz, 2H), 3.69 (d, J=12.4Hz, 1H), 2.87 (t, J=13.2Hz,
1H), 2.64 (t, J=6.0Hz, 2H), 2.36 (t, J=12.0Hz, 1H) .1.92 (s, 3H), 1.56-1.51 (m, 3H), 1.28
(t, J=7.2Hz, 3H)
MS(ESI),m/z:M+417.0;M-415.0.
Embodiment 3
1- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) cyclohexane carboxamide (E3)
(N-(1-acetylcyclohexyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E3)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.58 (d, J=8.4Hz, 1H), 8.15 (d, J=7.2Hz, 1H), 8.09 (d,
J=7.6Hz, 1H), 7.96 (t, J=8.0Hz, 1H), 7.31 (d, J=7.6Hz, 1H), 3.92 (q, J=6.8Hz, 2H),
3.26-3.21 (m, 4H), 1.25 (t, J=7.2Hz, 3H), 1.01-0.98 (m, 6H) .MS (ESI), m/z:M-400.8.
Embodiment 4
1- ethyls-N- (2- (ethylsulfonyl) ethyl) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide
(E4)
(1-ethyl-N-(2-(ethylsulfonyl)ethyl)-2-oxo-1,2-dihydrobenzo[cd]indole-
6-sulfonamide)(E4)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.67 (d, J=8.4Hz, 1H), 8.17-8.10 (m, 2H), 7.97 (t, J=
8.0Hz, 1H), 7.35 (d, J=7.6Hz, 1H), 3.95 (q, J=6.8Hz, 2H), 3.18-3.04 (m, 6H), 1.26 (t, J=
6.8Hz, 3H), 1.13 (t, J=7.2Hz, 2H) .MS (ESI), m/z:M-395.0.
Embodiment 5
N- ((3,5- dimethyl -4,5- dihydro-isoxazoles -5- substitutions) methyl) -1- ethyl-2-oxo -1,2- dihydrobenzos
[cd] indoles -6- sulfonamide (E5)
(1-ethyl-N-((4-methylmorpholin-2-yl)methyl)-2-oxo-1,2-dihydrobenzo
[cd]indole-6-sulfonamide)(E5)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.68 (d, J=8.4Hz, 1H), 8.16 (d, J=7.2Hz, 1H), 8.06 (d,
J=7.6Hz, 1H), 7.99 (t, J=6.0Hz, 1H), 7.92 (t, J=7.6Hz, 1H), 7.28 (d, J=7.6Hz, 1H), 3.93
(q, J=7.2Hz, 1H), 3.54 (d, J=10.8Hz, 2H), 3.18 (t, J=10.4Hz, 1H), 2.82 (t, J=6.0Hz,
2H), 2.49-2.39 (m, 2H), 1.98 (s, 3H) .1.75 (t, J=8.4Hz, 1H), 1.44 (t, J=10.8Hz, 1H), 1.27-
1.23(m,4H).MS(ESI),m/z:M-388.1.
Embodiment 6
1- ethyls-N- ((3- isopropyl -4,5- dihydro-isoxazoles -5- substitutions) methyl) -2- oxo -1,2- dihydrobenzos
[cd] indoles -6- sulfonamide (E6)
(1-ethyl-N-((3-isopropyl-4,5-dihydroisoxazol-5-yl)methyl)-2-oxo-1,2-
dihydrobenzo[cd]indole-6-sulfonamide)(E6)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.70 (d, J=8.0Hz, 1H), 8.14-8.09 (m, 2H), 8.06 (d, J=
7.6Hz, 1H), 7.94 (t, J=7.6Hz, 1H), 7.29 (d, J=7.2Hz, 1H), 4.43-4.39 (m, 1H), 3.93 (q, J=
6.8Hz, 2H), 2.84-2.83 (m, 2H), 2.48 (s, 3H), 1.26 (t, J=6.8Hz, 1H) .0.98 (s, 6H) .MS (ESI),
m/z:M-400.0.
Embodiment 7
N- ((3,5- dimethyl -4,5- dihydro-isoxazole -5- bases) methyl) -1- ethyl-2-oxo -1,2- dihydrobenzos
(cd] indoles -6- sulfonamide (E7)
(N-((3,5-dimethyl-4,5-dihydroisoxazol-5-yl)methyl)-1-ethyl-2-oxo-1,2-
dihydrobenzo[cd]indole-6-sulfonamide)(E7)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.72 (d, J=8.4Hz, 1H), 8.15-8.10 (m, 2H), 8.07 (d, J=
7.6Hz, 1H), 7.94 (t, J=7.2Hz, 1H), 7.30 (d, J=7.6Hz, 1H), 3.93 (q, J=7.2Hz, 2H), 2.85-
2.82(m,3H),2.58(s,1H),1.75(s,3H).1.27-1.22(m,4H),1.17(s,2H).MS(ESI),m/z:M-
386.0.
Embodiment 8
1- ethyls-N- ((5- methyl isophthalic acid H- indazole -3- bases) methyl) -2- oxo -1,2- dihydrobenzos (cd] indoles -6- sulphurs
Acid amides (E8)
(1-ethyl-N-((5-methyl-1H-indazol-3-yl)methyl)-2-oxo-1,2-dihydrobenzo
[cd]indole-6-sulfonamide)(E8)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 12.49 (s, 1H), 8.59 (d, J=8.4Hz, 1H), 8.39 (t, J=
5.6Hz, 1H), 8.03 (d, J=7.2Hz, 1H), 7.83 (q, J=7.2Hz, 1H), 7.76 (d, J=7.6Hz, 1H), 7.07 (d,
J=8.4Hz, 1H), 6.97 (d, J=7.6Hz, 1H), 6.87 (s, 1H), 6.81 (d, J=8.4Hz, 1H), 4.33 (d, J=
5.6Hz, 2H), 3.85 (q, J=7.2Hz, 2H), 1.98 (s, 3H), 1.27 (t, J=7.2Hz, 3H) .MS (ESI), m/z:M+
421.0;M-419.0.
Embodiment 9
1- ethyls-N- ((4- methyl -6- (trifluoromethyl) pyrimidines -2- substitutions) methyl) -2- oxo -1,2- dihydrobenzos
[cd] indoles -6- sulfonamide (E9)
(1-ethyl-N-((4-methyl-6-(trifluoromethyl)pyrimidin-2-yl)methyl)-2-
oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide)(E9)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.72 (t, J=6.4Hz, 1H), 8.61 (d, J=8.4Hz, 1H), 8.08 (d,
J=6.8Hz, 1H), 7.89-7.84 (m, 2H), 7.43 (s, 1H), 7.07 (d, J=7.6Hz, 1H), 4.36 (d, J=6.4Hz,
1H), 3.87 (q, J=7.2Hz, 2H), 2.09 (s, 3H), 1.22 (t, J=7.2Hz, 3H) .MS (ESI), m/z:M-449.0.
Embodiment 10
The tert-butyl group (3- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) phenyl) amino first
Tert-butyl acrylate (E10)
(tert-butyl(3-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamido)phenyl)carbamate)(E10)
1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonic acid chlorides synthetic method such as embodiment 1.
Take 1- ethyl-2-oxos -1,2- dihydrobenzo [cd] indoles -6- sulfonic acid chlorides (60mg, 0.203mmol), DAMP
(5mg, 0.041mmol) and the tert-butyl group (3- aminophenyls) t-butyl carbamate (85mg, 0.406mmol) are dissolved in 10mLDMF
In, add triethylamine 2mL.Overnight, after reaction completely, washing, ethyl acetate extracts three times, merges organic layer for room temperature reaction,
10% hydrochloric acid 50mL is washed once, and saturated sodium-chloride water solution is washed once, anhydrous sodium sulfate drying, column chromatography, it is yellowish green to obtain 54mg
Color pulverulent solids, yield 58%.
1H-NMR (400MHz, d-DMSO) δ 8.58 (d, J=8.4Hz, 1H), 8.17 (d, J=8.0Hz, 1H), 8.00 (d,
J=7.2Hz, 1H), 7.68 (d, J=7.6Hz, 1H), 7.17 (s, 1H), 7.01 (t, J=8.2Hz, 2H), 6.83 (d, J=
7.6Hz, 1H), 6.73 (d, J=7.2Hz, 1H), 6.63 (s, 1H), 3.91 (dd, J=14.2Hz, 7.0Hz, 2H), 1.43 (s,
9H), 1.25 (t, J=7.0Hz, 3H) .MS (ESI), m/z:M-446.1.
Embodiment 11
N- (3,4- Dimethoxyphenyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E11)
(N-(3,4-dimethoxyphenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E11)
Synthetic method such as embodiment 10.
1H-NMR (400MHz, d-DMSO) δ 8.55 (d, J=8.4Hz, 1H), 8.04 (t, J=3.6Hz, 2H), 7.72 (t,
J=7.4Hz, 1H), 7.36-7.23 (m, 1H), 6.82 (d, J=7.6Hz, 1H), 6.64 (s, 1H), 6.55 (d, J=8.8Hz,
1H), 6.41 (d, J=8.4Hz, 1H), 3.93 (dd, J=14.0Hz, 6.8Hz, 2H), 3.73 (s, 3H), 3.65 (s, 3H),
1.24 (t, J=7.0Hz, 3H) .MS (ESI), m/z:M+413.1;M-411.0.
Embodiment 12
1- ethyls-N- ((1- methyl -5- (trifluoromethyl) -1H- benzo [d] imidazoles -2- substitutions) methyl) -2- oxo -1,
2- dihydrobenzos [cd] indoles -6- sulfonamide (E12)
(1-ethyl-N-((1-methyl-5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)
methyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide)(E12)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.70 (t, J=6.0Hz, 1H), 8.56 (d, J=8.4Hz, 1H), 7.96 (d,
J=7.2Hz, 1H), 7.91 (d, J=7.6Hz, 1H), 7.85 (t, J=8.0Hz, 1H), 7.49 (s, 1H), 7.35 (s, 1H),
6.95 (d, J=7.6Hz, 1H), 4.41 (d, J=5.6Hz, 2H), 3.73 (q, J=7.2Hz, 2H), 3.51 (s, 3H), 1.14
(t, J=7.2Hz, 3H)
MS(ESI),m/z:M+489.0;M-487.0.
Embodiment 13
1- ethyls-N- ((the fluoro- 1H- indoles -2- substitutions of 5-) methyl) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulphurs
Acid amides (E13)
(1-ethyl-N-((5-fluoro-1H-indol-2-yl)methyl)-2-oxo-1,2-dihydrobenzo
[cd]indole-6-sulfonamide)(E13)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 10.78 (s, 1H) 8.68 (d, J=8.4Hz, 1H), 8.33 (t, J=5.6Hz,
1H), 8.04-8.01 (m, 2H), 7.88 (d, J=7.6Hz, 1H), 7.16 (d, J=7.6Hz, 1H), 7.09 (t, J=4.8Hz,
1H), 6.94 (dd, J=2.4Hz, J=2.0Hz, 1H), 6.77-6.72 (m, 1H), 5.94 (s, 1H), 4.13 (d, J=5.6Hz,
2H), 3.87 (q, J=7.2Hz, 2H), 1.23 (t, J=7.2Hz, 3H) .MS (ESI), m/z:M-422.0.
Embodiment 14
1- ethyls-N- ((5- methoxyl group-1H- indoles-2-substitution) methyl)-2- oxo base-1,2- dihydrobenzos [cd] Yin
Diindyl -6- sulfonamide (14)
(1-ethyl-N-((5-methoxy-1H-indol-2-yl)methyl)-2-oxo-1,2-dihydrobenzo
[cd]indole-6-sulfonamide)(E14)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 10.51 (s, 1H), 8.65 (d, J=12.4Hz, 1H), 8.26 (t, J=
6.0Hz, 1H), 8.05-8.01 (m, 2H), 7.87 (t, J=7.6Hz, 1H), 7.14 (d, J=7.6Hz, 1H), 7.02 (d, J=
8.4Hz, 1H), 6.68 (s, 1H), 6.56 (dd, J=1.6Hz, J=1.6Hz, 1H), 5.82 (s, 1H), 4.11 (d, J=
6.0Hz, 2H), 3.86 (q, J=7.2Hz, 2H), 3.66 (s, 1H) .1.28 (t, J=6.8Hz, 3H) .MS (ESI), m/z:M+
436.0;M-434.0.
Embodiment 15
1- ethyls-N- (3- methyl isophthalic acids-(pyridine -3- substitutions) butyl) -2- oxo -1,2- dihydrobenzo [cd] indoles -6-
Sulfonamide (E15)
(1-ethyl-N-(3-methyl-1-(pyridin-3-yl)butyl)-2-oxo-1,2-dihydrobenzo
[cd]indole-6-sulfonamide)(E15)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.53 (d, J=8.4Hz, 1H), 8.44 (d, J=9.2Hz, 1H), 8.05 (d,
J=7.2Hz, 1H), 7.99 (s, 1H), 7.92-7.82 (m, 3H), 7.21 (d, J=7.6Hz, 1H), 7.05 (d, J=7.6Hz,
1H), 6.65 (dd, J=4.8Hz, J=4.8Hz, 2H), 4.17 (q, J=9.2Hz, 1H), 9.91-3.80 (m, 2H), 1.57-
1.50 (m, 1H), 1.45-1.39 (m, 1H) .0.76 (d, J=5.6Hz, 3H), 0.69 (d, J=6.4Hz, 3H) .MS (ESI), m/
z:M-442.1.
Embodiment 16
1-N- (4- chloro- 3- (trifluoromethyl) phenyl) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulphonyl
Amine (E16)
(N-(4-chloro-3-(trifluoromethyl)phenyl)-1-ethyl-2-oxo-1,2-
dihydrobenzo[cd]indole-6-sulfonamide)(E16)
Synthetic method such as embodiment 10.
1H-NMR (400MHz, d-DMSO) δ 11.12 (s, 1H), 8.65 (d, J=8.4Hz, 1H), 8.19 (d, J=
7.6Hz, 1H), 8.14 (d, J=6.8Hz, 1H), 7.96 (t, J=7.8Hz, 1H), 7.53 (d, J=8.8Hz, 1H), 7.46 (d,
J=1.6Hz, 1H), 7.31 (dd, J=14.2Hz, 8.2Hz, 2H), 3.89 (dd, J=14.2Hz, 7.0Hz, 2H), 1.23 (t, J
=7.0Hz, 3H)
MS(ESI),m/z:M+457.0;M-453.0.
Embodiment 17
N- (4- acetylphenyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E17)
(N-(4-acetylphenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E17)
Synthetic method such as embodiment 10.
1H-NMR (400MHz, d-DMSO) δ 10.82 (s, 1H), 8.69 (d, J=8.4Hz, 1H), 8.19 (d, J=
7.6Hz, 1H), 8.09 (d, J=7.2Hz, 1H), 7.94 (t, J=8.0Hz, 1H), 7.58-7.53 (m, 2H), 7.31 (d, J=
5.6Hz, 2H), 7.25 (d, J=7.6Hz, 1H), 3.86 (q, J=6.8Hz, 2H), 2.43 (s, 3H), 1.22 (t, J=6.8Hz,
3H).MS(ESI),m/z:M+395.0;M-393.0.
Embodiment 18
N- (benzo [d] [1,3] dioxole-5-substituent methyl)-1- ethyl-2-oxo-1,2- dihydrobenzos
[cd] indoles -6- sulfonamide (E18)
(N-(benzo[d][1,3]dioxol-5-ylmethyl)-1-ethyl-2-oxo-1,2-dihydrobenzo
[cd]indole-6-sulfonamide)(E18)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.62 (d, J=8.4Hz, 1H), 8.31 (t, J=6.4Hz, 1H), 8.11 (d,
J=6.8Hz, 1H), 8.01 (d, J=7.6Hz, 1H), 7.90 (t, J=7.6Hz, 1H), 7.21 (d, J=7.6Hz, 1H), 6.54
(d, J=7.6Hz, 1H), 6.46 (d, J=7.6Hz, 2H), 5.80 (s, 2H), 3.91 (d, J=6.8Hz, 1H), 1.27 (t, J=
6.8Hz,3H).MS(ESI),m/z:M+411.0;M-409.1.
Embodiment 19
1- ethyls-N- (4- morphlinophenyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E19)
(1-ethyl-N-(4-morpholinophenyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E19)
Synthetic method such as embodiment 10.
1H-NMR (400MHz, d-DMSO) δ 10.08 (s, 1H), 8.65 (d, J=8.4Hz, 1H), 8.11 (d, J=
6.8Hz, 1H), 8.00 (d, J=7.6Hz, 1H), 7.86 (t, J=8.4Hz, 1H), 7.20 (d, J=7.6Hz, 1H), 6.87 (d,
J=8.8Hz, 2H), 6.70 (d, J=9.2Hz, 2H), 3.87 (q, J=6.8Hz, 2H), 3.62-3.60 (m, 4H), 2.91-
2.89 (m, 4H), 1.22 (t, J=7.2Hz, 3H) .MS (ESI), m/z:M+438.0;M-436.0.
Embodiment 20
1- ethyl-2-oxos-N- (pyridine -2- ylmethyls) -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E20)
(1-ethyl-2-oxo-N-(pyridin-2-ylmethyl)-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E20)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.66 (d, J=8.4Hz, 1H), 8.49 (t, J=6.0Hz, 1H), 8.21 (d,
J=4.4Hz, 1H), 8.11 (d, J=6.8Hz, 1H), 8.02 (d, J=7.6Hz, 1H), 7.91 (t, J=8.0Hz, 1H),
7.50-7.46 (m, 1H), 7.20-7.15 (m, 2H), 7.05-7.02 (m, 1H), 4.11 (d, J=6.4Hz, 2H), 3.89 (q, J
=7.2Hz, 2H), 1.26 (t, J=6.8Hz, 3H) .MS (ESI), m/z:M+368.0;M-366.0.
Embodiment 21
1- ethyls-N- (4- methyl-benzyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E21)
(1-ethyl-N-(4-methylbenzyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E21)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.64 (d, J=8.4Hz, 1H), 8.33 (t, J=6.4Hz, 1H), 8.11 (d,
J=7.2Hz, 1H), 8.01 (d, J=7.6Hz, 1H), 7.88 (t, J=7.6Hz, 1H), 7.19 (t, J=7.6Hz, 1H), 6.89
(d, J=8.0Hz, 2H), 6.81 (d, J=8.0Hz, 2H), 3.94-3.87 (m, 4H), 2.10 (s, 3H), 1.26 (t, J=
7.2Hz,3H).MS(ESI),m/z:M-379.0.
Embodiment 22
N- (4- (tert-butyl group) benzyl) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E22)
(N-(4-(tert-butyl)benzyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E22)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.62 (d, J=8.8Hz, 1H), 8.35 (t, J=6.4Hz, 1H), 8.09 (d,
J=6.8Hz, 1H), 7.88 (d, J=7.6Hz, 1H), 7.20 (d, J=7.6Hz, 1H), 7.00 (d, J=8.0Hz, 2H), 6.92
(d, J=8.4Hz, 2H), 3.97 (d, J=6.4Hz, 2H), 3.87 (q, J=6.8Hz, 2H), 1.25 (t, J=7.2Hz, 3H),
1.10(s,9H).MS(ESI),m/z:M-421.2.
Embodiment 23
1- ethyls-N- (4- fluorobenzene ethyl) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E23)
(1-ethyl-N-(4-fluorophenethyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E23)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.55 (d, J=8.4Hz, 1H), 8.09 (d, J=6.8Hz, 1H), 7.99 (d,
J=7.6Hz, 1H), 7.89-7.85 (m, 2H), 7.20 (d, J=7.6Hz, 1H), 6.97-6.94 (m, 2H), 6.74 (t, J=
8.8Hz, 2H), 3.90 (q, J=6.8Hz, 2H), 3.02 (q, J=6.8Hz, 2H), 2.57 (t, J=6.8Hz, 2H), 1.26 (t,
J=7.2Hz, 3H) .MS (ESI), m/z:M-397.0.
Embodiment 24
N- ((2,2- dimethyl -1,3- dioxolanes -4- bases) methyl) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd]
Indoles -6- sulfonamide (E24)
(N-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-1-ethyl-2-oxo-1,2-
dihydrobenzo[cd]indole-6-sulfona mide)(E24)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.68 (d, J=8.4Hz, 1H), 8.16 (d, J=6.8Hz, 1H), 8.09-
8.03 (m, 2H), 7.95-9-7.91 (m, 1H), 7.29 (d, J=7.6Hz, 1H), 3.98-9.90 (m, 2H), 3.84 (q, J=
6.0Hz, 1H), 3.54 (q, J=5.6Hz, 1H), 2.84 (t, J=6.0Hz, 2H), 1.27 (t, J=7.2Hz, 3H), 1.14 (s,
3H),1.11(s,3H).MS(ESI),m/z:M-389.1.
Embodiment 25
1- ethyls-N- (2- morpholinoethyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E25)
(1-ethyl-N-(2-morpholinoethyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E25)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.68 (d, J=8.4Hz, 1H), 8.15 (d, J=6.8Hz, 1H), 8.09 (d,
J=7.6Hz, 1H), 7.95 (q, J=7.2Hz, 1H), 7.71 (s, 1H), 7.29 (d, J=7.6Hz, 1H), 3.93 (q, J=
7.2Hz, 2H), 3.25 (t, J=4.4,4H), 2.89 (s, 2H), 2.19 (t, J=6.4Hz, 2H), 2.07 (d, J=4.0Hz,
4H), 1.26 (t, J=8.8Hz, 3H)
MS(ESI),m/z:M+390.1;M-388.1.
Embodiment 26
1- ethyls-N- (4- methoxy-benzyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E26)
(1-ethyl-N-(4-methoxybenzyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E26)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.63 (d, J=8.4Hz, 1H), 8.28 (t, J=6.4Hz, 1H), 8.11 (d,
J=6.8Hz, 1H), 8.00 (d, J=7.6Hz, 1H), 7.90 (q, J=7.2Hz, 1H), 7.21 (d, J=7.6Hz, 1H), 6.94
(d, J=8.4Hz, 2H), 6.57 (d, J=8.8Hz, 2H), 2.93-3.88 (m, 5H), 3.60 (s, 3H), 1.27 (t, J=
7.2Hz,3H).MS(ESI),m/z:[M+H]-,395.1.
Embodiment 27
1- ethyls-N- (3- methyl-benzyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E27)
(1-ethyl-N-(3-methylbenzyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E27)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.65 (d, J=8.4Hz, 1H), 8.34 (t, J=6.4Hz, 1H), 8.11 (d,
J=7.2Hz, 1H), 7.99 (d, J=7.6Hz, 1H), 7.91 (t, J=8.0Hz, 1H), 7.19 (d, J=7.6Hz, 1H), 6.93
(t, J=7.6Hz, 1H), 6.84-6.80 (m, 2H), 6.71 (s, 1H), 3.98 (d, J=6.4Hz, 2H), 3.90 (q, J=
6.8Hz, 2H), 1.98 (s, 3H), 1.27 (t, J=7.2Hz, 3H) .MS (ESI), m/z:M-379.1.
Embodiment 28
N- ((6- chloropyridines -3- substitutions) methyl) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide
(E28)
(N-((6-chloropyridin-3-yl)methyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]
indole-6-sulfonamide)(E28)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.57 (d, J=8.4Hz, 1H), 8.48 (t, J=6.4Hz, 1H), 8.11 (d,
J=6.8Hz, 1H), 7.98-7.97 (m, 2H), 7.90 (q, J=7.2Hz, 1H), 7.44-7.41 (m, 1H), 7.21 (d, J=
7.6Hz, 1H), 7.03 (d, J=8.0Hz, 1H), 4.06 (d, J=6.4Hz, 1H), 3.91 (q, J=7.2Hz, 2H), 1.27 (t,
J=8.8Hz, 3H) .MS (ESI), m/z:M-400.0
Embodiment 29
1- ethyls-N- (the fluoro- 4- methyl-benzyls of 3-) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E29)
(1-ethyl-N-(3-fluoro-4-methylbenzyl)-2-oxo-1,2-dihydrobenzo[cd]
indole-6-sulfonamide)(E29)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.64 (d, J=8.4Hz, 1H), 8.40 (s, 1H), 8.13 (d, J=6.8Hz,
1H), 8.00 (d, J=7.6Hz, 1H), 7.86 (t, J=8.0Hz, 1H), 7.14 (d, J=7.6Hz, 1H), 6.86 (t, J=
8.8Hz, 1H), 6.65 (t, J=6.4Hz, 1H), 3.97 (s, 2H), 3.90 (q, J=7.2Hz, 2H), 1.96 (s, 3H), 1.27
(t, J=7.2Hz, 3H) .MS (ESI), m/z:M-397.1.
Embodiment 30
N- (the chloro- 6- luorobenzyls of 2-) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E30)
(N-(2-chloro-6-fluorobenzyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]
indole-6-sulfonamide)(E30)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.63 (d, J=8.4Hz, 1H), 8.37 (t, J=6.0Hz, 1H), 8.10 (d,
J=6.8Hz, 1H), 8.04 (d, J=7.6Hz, 1H), 7.86 (q, J=6.8Hz, 1H), 7.20 (d, J=7.6Hz, 1H),
7.13-7.07 (m, 1H), 6.98 (d, J=8.0Hz, 1H), 6.85 (d, J=8.8Hz, 1H), 4.13 (d, J=4.8Hz, 1H),
3.92 (q, J=6.8Hz, 1H), 1.27 (t, J=6.8Hz, 3H)
MS(ESI),m/z:M-417.0.
Embodiment 31
N- (4- chlorobenzene ethyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E31)
(N-(4-chlorophenethyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E31)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.55 (d, J=8.0Hz, 1H), 8.11 (d, J=7.2Hz, 1H), 7.98 (d,
J=7.6Hz, 1H), 7.89-7.85 (m, 2H), 7.21 (d, J=7.6Hz, 1H), 6.95 (s, 4H), 3.94 (q, J=7.2Hz,
2H), 3.08 (q, J=6.8Hz, 2H), 2.59 (t, J=6.8Hz, 2H), 1.29 (t, J=7.2Hz, 3H) .MS (ESI), m/z:
M-413.0.
Embodiment 32
1- ethyls-N- (4- luorobenzyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E32)
(1-ethyl-N-(4-fluorobenzyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E32)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.64 (d, J=8.4Hz, 1H), 8.40 (t, J=6.4Hz, 1H), 8.13 (d,
J=6.8Hz, 1H), 8.02 (d, J=7.6Hz, 1H), 7.89 (q, J=7.2Hz, 1H), 7.20 (d, J=7.6Hz, 1H),
7.10-7.07 (m, 2H), 6.89-6.83 (m, 2H), 4.01 (d, J=6.4Hz, 2H), 3.88 (q, J=7.2Hz, 2H), 1.27
(t, J=7.2Hz, 3H) .MS (ESI), m/z:M-383.0.
Embodiment 33
N- (2- chlorobenzyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E33)
(N-(2-chlorobenzyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E33)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.68 (d, J=8.0Hz, 1H), 8.13 (d, J=7.2Hz, 1H), 8.04 (d,
J=7.6Hz, 1H), 7.92 (t, J=7.2Hz, 1H), 7.27-7.29 (m, 3H), 7.12-7.02 (m, 2H), 4.12 (s, 2H),
3.93 (q, J=7.2Hz, 1H), 1.27 (t, J=7.2Hz, 3H) .MS (ESI), m/z:M-399.0.
Embodiment 34
1- ethyls-N- (3- morphoinopropyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E34)
(1-ethyl-N-(3-morpholinopropyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E34)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.69 (d, J=8.0Hz, 1H), 8.17 (d, J=6.8Hz, 1H), 8.07 (d,
J=7.6Hz, 1H), 7.94 (t, J=8.0Hz, 1H), 7.79 (s, 1H), 7.31 (d, J=7.6Hz, 1H), 3.95 (q, J=
7.2Hz, 2H), 3.37 (s, 4H), 2.82 (d, J=5.2Hz, 2H), 2.06-2.02 (m, 6H), 1.42 (t, J=6.8Hz, 2H),
1.28 (t, J=6.8Hz, 3H) .MS (ESI), m/z:M+403.5;M-402.1.
Embodiment 35
1- ethyls-N- (2- luorobenzyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E35)
(1-ethyl-N-(2-fluorobenzyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E35)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.64 (d, J=8.4Hz, 1H), 8.41 (s, 1H), 8.12 (d, J=6.8Hz,
1H), 8.03 (d, J=8.0Hz, 1H), 7.91 (t, J=7.2Hz, 1H), 7.21 (d, J=7.6Hz, 1H), 7.15 (t, J=
8.0Hz, 1H), 7.07-7.05 (m, 1H), 7.91-7.83 (m, 2H), 4.06 (s, 2H), 3.92 (q, J=7.2Hz, 2H), 1.29
(t, J=7.2Hz, 3H) .MS (ESI), m/z:M-383.0.
Embodiment 36
N- (1- acetyl group-4-substitution)-1- ethyl-2-oxo-1,2- dihydrobenzos [cd] indoles-6-sulfonamide (E36)
(N-(1-acetylpiperidin-4-yl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-
6-sulfonamide)(E36)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.70 (d, J=8.4Hz, 1H), 8.16-8.11 (m, 2H), 8.02 (d, J=
7.6Hz, 1H), 7.94 (q, J=7.2Hz, 1H), 7.30 (d, J=8.0Hz, 1H), 4.01 (q, J=6.8Hz, 1H), 3.93 (q,
J=7.2Hz, 2H), 3.58 (d, J=14.0Hz, 1H), 3.33-3.19 (m, 1H), 2.97-2.90 (m, 1H), 2.62-2.55
(m, 1H), 1.88 (s, 3H), 1.49 (d, J=10.0Hz, 2H), 1.28 (t, J=7.2Hz, 3H), 1.27-1.22 (m, 2H) .MS
(ESI),m/z:M+402.1;M-400.1.
Embodiment 37
1- ethyls-N- (2- methyl-benzyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E37)
(1-ethyl-N-(2-methylbenzyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E37)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.70 (d, J=8.4Hz, 1H), 8.22 (s, 1H), 8.13 (d, J=6.8Hz,
1H), 8.06 (d, J=7.6Hz, 1H), 7.94-7.90 (m, 1H), 7.25 (d, J=7.6Hz, 1H), 7.09 (d, J=7.2Hz,
1H), 6.99-6.92 (m, 3H), 3.98-3.90 (m, 4H), 2.09 (s, 3H), 1.28 (t, J=6.8Hz, 3H) .MS (ESI), m/
z:M-379.1.
Embodiment 38
1- ethyls-6- ((4- (pyridin-4-yl methyl) piperazine-1-substitution) sulfonyl) benzo [cd] indoles-2 (1H) -one
(E38)
(1-ethyl-6-((4-(pyridin-4-ylmethyl)piperazin-1-yl)sulfonyl)benzo[cd]
indol-2(1H)-one)(E38)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.64 (d, J=8.4Hz, 1H), 8.40-8.38 (m, 2H), 8.16 (d, J=
7.2Hz, 1H), 8.07 (d, J=7.6Hz, 1H), 7.94 (dd, J=7.2Hz;J=7.2Hz, 1H), 7.38 (d, J=7.6Hz,
1H), 7.16 (d, J=6.8Hz, 2H), 3.94 (q, J=6.8Hz, 2H), 3.44 (s, 2H), 3.00 (s, 4H), 2.40-2.38
(m, 4H), 1.29 (t, J=7.2Hz, 3H) .MS (ESI), m/z:M+437.5;M-436.1.
Embodiment 39
N- (2- chlorobenzene ethyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E39)
(N-(2-chlorophenethyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E39)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.60 (d, J=8.4Hz, 1H), 8.14 (d, J=7.2Hz, 1H), 8.06 (d,
J=7.6Hz, 1H), 8.00 (t, J=5.6Hz, 1H), 7.91 (t, J=8.0Hz, 1H), 7.26 (d, J=7.6Hz, 1H), 7.18
(d, J=7.6Hz, 1H), 7.11 (d, J=6.8Hz, 1H), 7.05-6.97 (m, 2H), 3.93 (q, J=7.2Hz, 2H), 3.06
(q, J=6.4Hz, 2H), 2.69 (t, J=7.2Hz, 2H), 1.29 (t, J=7.2Hz, 3H) MS (ESI), m/z:M-413.1.
Embodiment 40
1- ethyl-2-oxos-N- (4- (trifluoromethyl) benzyl) -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E40)
(1-ethyl-2-oxo-N-(4-(trifluoromethyl)benzyl)-1,2-dihydrobenzo[cd]
indole-6-sulfonamide)(E40)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.60 (d, J=8.4Hz, 1H), 8.52 (s, 1H), 8.10 (d, J=6.8Hz,
1H), 7.99 (d, J=7.2Hz, 1H), 7.88 (t, J=7.6Hz, 1H), 7.32 (d, J=8.0Hz, 2H), 7.22 (d, J=
8.0Hz, 2H), 7.15 (d, J=7.6Hz, 1H), 4.15 (s, 2H), 3.89 (d, J=7.2Hz, 2H), 1.25 (t, J=6.8Hz,
3H).MS(ESI),m/z:M-433.0.
Embodiment 41
N- (double (trifluoromethyl) benzyls of 3,5-) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide
(E41)
(N-(3,5-bis(trifluoromethyl)benzyl)-1-ethyl-2-oxo-1,2-dihydrobenzo
[cd]indole-6-sulfonamide)(E41)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.66 (t, J=6.0Hz, 1H), 8.57 (d, J=8.4Hz, 1H), 8.08 (d,
J=7.2Hz, 1H), 7.95 (d, J=7.6Hz, 1H), 7.85 (t, J=7.6Hz, 1H), 7.62 (s, 3H), 7.10 (d, J=
7.6Hz, 1H), 4.34 (d, J=6.0Hz, 2H), 3.87 (q, J=7.2Hz, 2H), 1.22 (t, J=6.8Hz, 3H) .MS
(ESI),m/z:M-501.0.
Embodiment 42
1- ethyls-N- (4- fluoro- 3- (trifluoromethyl) benzyl) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide
(E42)
(1-ethyl-N-(4-fluoro-3-(trifluoromethyl)benzyl)-2-oxo-1,2-
dihydrobenzo[cd]indole-6-sulfonamide)(E42)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.59 (d, J=8.4Hz, 1H), 8.51 (t, J=6.0Hz, 1H), 8.10 (d,
J=7.2Hz, 1H), 7.94-7.87 (m, 2H), 7.39 (s, 1H), 7.17-7.10 (m, 3H), 4.15 (d, J=6.4Hz, 2H),
3.89 (q, J=6.8Hz, 2H), 1.23 (t, J=7.2Hz, 3H) .MS (ESI), m/z:M-451.0.
Embodiment 43
N- (the bromo- 2- luorobenzyls of 4-) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E43)
(N-(4-bromo-2-fluorobenzyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-
6-sulfonamide)(E43)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.66 (d, J=8.4Hz, 1H), 8.13 (d, J=5.6Hz, 1H), 8.05 (d,
J=7.6Hz, 1H), 7.95 (t, J=7.6Hz, 1H), 7.38 (q, J=5.6Hz, 1H), 7.20 (d, J=7.6Hz, 1H), 6.96
(t, J=7.2Hz, 1H), 6.87-8-6.83 (m, 1H), 4.11 (s, 2H), 3.92 (q, J=6.8Hz, 2H), 1.25 (t, J=
6.8Hz,3H).MS(ESI),m/z:M-460.9.
Embodiment 44
1- ethyl-2-oxos-N- (3,4,5- trifluoro-benzyls) -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E44)
(1-ethyl-2-oxo-N-(3,4,5-trifluorobenzyl)-1,2-dihydrobenzo[cd]indole-
6-sulfonamide)(E44)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.60 (d, J=8.0Hz, 1H), 8.50 (s, 1H), 8.12 (d, J=6.8Hz,
1H), 8.00 (d, J=7.6Hz, 1H), 7.91 (t, J=7.6Hz, 1H), 7.21 (d, J=7.6Hz, 1H), 6.85 (t, J=
8.0Hz, 1H), 4.06 (s, 2H), 3.91 (q, J=6.8Hz, 2H), 1.25 (t, J=7.2Hz, 3H) .MS (ESI), m/z:M-
419.0.
Embodiment 45
N- (2,5- dichloro benzyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E45)
(N-(2,5-dichlorobenzyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E45)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.68 (d, J=8.4Hz, 1H), 8.28 (t, J=5.2Hz, 1H), 8.12-
8.09 (m, 1H), 7.88 (t, J=8.0Hz, 1H), 7.26 (d, J=7.6Hz, 1H), 7.19 (d, J=7.2Hz, 2H), 7.18-
7.11 (m, 1H), 4.25 (d, J=5.2Hz, 2H), 3.93 (q, J=7.2Hz, 2H), 1.27 (t, J=7.2Hz, 3H) .MS
(ESI),m/z:M-433.0.
Embodiment 46
N- (2,4 difluorobenzene base) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E46)
(N-(2,4-difluorophenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E46)
Synthetic method such as embodiment 10.
1H-NMR (400MHz, d-DMSO) δ 8.22 (d, J=8.0Hz, 1H), 8.10 (d, J=6.8Hz, 1H), 7.94 (d,
J=8.4Hz, 1H), 7.67 (t, J=7.6Hz, 1H), 7.41-7.34 (m, 1H), 7.32-7.28 (m, 1H), 7.26-7.22 (m,
1H), 3.95 (q, J=7.2Hz, 2H), 1.29 (t, J=6.8Hz, 3H) .MS (ESI), m/z:M-387.0.
Embodiment 47
1- ethyls-N- ((1- ethyl-2-oxo-1-1,2- dihydrobenzos [cd] indoles-6-substitution) sulfonyl)-N- (5-
Fluoro-2-methylbenzene base) -2- oxo 1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E47)
(1-ethyl-N-((1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfonyl)-
N-(5-fluoro-2-methylphenyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide)
(E47)
Synthetic method such as embodiment 10.
1H-NMR (400MHz, d-DMSO) δ 8.23 (d, J=8.0Hz, 2H), 8.12 (d, J=6.8Hz, 2H), 8.03 (d,
J=8.4Hz, 2H), 7.74 (t, J=7.6Hz, 2H), 7.38 (d, J=8.0Hz, 2H), 7.31 (d, J=5.6Hz, 2H), 6.64
(d, J=8.8Hz, 1H), 3.98 (d, J=7.2Hz, 4H), 1.77 (s, 3H), 1.31 (t, J=7.2Hz, 3H) .MS (ESI), m/
z:M-643.70.
Embodiment 48
N- (1- benzyl piepridines-4-substitution)-1- ethyl-2-oxo-1,2- dihydrobenzos [cd] indoles-6- sulfonamide
(E48)
(N-(1-benzylpiperidin-4-yl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-
6-sulfonamide)(E48)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.70 (d, J=8.0Hz, 1H), 8.13-8.08 (m, 2H), 7.95-7.91
(m, 2H), 7.27-7.22 (m, 3H), 7.14 (d, J=6.8Hz, 3H), 3.91 (d, J=6.8Hz, 2H), 3.30 (s, 2H),
2.95 (s, 1H), 2.57-2.50 (m, 2H) 1.78 (t, J=6.8Hz, 3H), 1.45-1.42 (m, 2H), 1.33-1.24 (m,
5H).MS(ESI),m/z:M+450.2;M-448.2.
Embodiment 49
6- ((4- (2- chlorphenyls) piperazine -1- substitutions) sulfonyl) -1- ethyls benzo [cd] indoles -2 (1H) -one (E49)
(6-((4-(2-chlorophenyl)piperazin-1-yl)sulfonyl)-1-ethylbenzo[cd]
indol-2(1H)-one)(E49)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.69 (d, J=8.4Hz, 1H), 8.17 (d, J=6.8Hz, 1H), 8.12 (d,
J=7.6Hz, 1H), 7.98 (t, J=7.6Hz, 1H), 7.38 (d, J=7.6Hz, 1H), 7.13 (t, J=8.0Hz, 1H), 6.88
(s, 1H), 6.81 (d, J=8.4Hz, 1H), 6.75 (d, J=7.6Hz, 1H), 3.95 (q, J=6.8Hz, 2H), 3.20 (s,
4H), 3.09 (s, 4H), 1.28 (t, J=7.2Hz, 3H) .MS (ESI), m/z:M-445.0.
Embodiment 50
N- ([1,1'- biphenyl]-3-substitution)-1- ethyl-2-oxo-1,2- dihydrobenzos [cd] indoles-6- sulfonamide
(E50)
(N-([1,1'-biphenyl]-3-yl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E50)
Synthetic method such as embodiment 10.
1H-NMR (400MHz, d-DMSO) δ 10.7 (s, 1H), 8.74 (d, J=8.4Hz, 1H), 8.21 (d, J=7.6Hz,
1H), 8.08 (d, J=6.8Hz, 1H), 7.92 (t, J=7.6Hz, 1H), 7.41 (s, 4H), 7.26-7.22 (m, 5H), 7.05
(d, J=6.8Hz, 1H), 3.86 (d, J=6.8Hz, 2H), 1.22 (t, J=6.8Hz, 3H) .MS (ESI), m/z:M-427.0.
Embodiment 51
Tert-butyl group 4- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) piperidines -1- formic acid
The tert-butyl ester (E51)
(tert-butyl4-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)
piperidine-1-carboxylate)(E51)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.68 (d, J=8.4Hz, 1H), 8.15-8.10 (m, 2H), 7.98-7.92
(m, 2H), 7.29 (d, J=7.6Hz, 1H), 3.93 (d, J=7.2Hz, 2H), 3.67-3.64 (m, 2H), 3.18 (s, 1H),
2.69(s,2H),1.47-1.44(m,2H),1.32(s,9H),1.32-1.25(m,3H),1.17-1.51(m,2H).MS
(ESI),m/z:M-458.0.
Embodiment 52
N- (3- chlorobenzene ethyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (52)
(N-(3-chlorophenethyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E52)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.55 (d, J=8.4Hz, 1H), 8.12 (d, J=6.8Hz, 1H), 8.01 (d,
J=7.6Hz, 1H), 7.88-7.85 (m, 2H), 7.25 (d, J=7.6Hz, 1H), 7.03-6.99 (m, 3H), 6.92 (d, J=
6.8Hz, 1H), 3.95 (q, J=7.2Hz, 2H), 3.08 (q, J=6.0Hz, 3H), 2.62 (t, J=6.4Hz, 2H), 1.30 (t,
J=6.8Hz, 3H) .MS (ESI), m/z:M-413.0.
Embodiment 53
N- benzhydryls -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E53)
(N-benzhydryl-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide)
(E53)
Synthetic method such as embodiment 10.
1H-NMR (400MHz, d-DMSO) δ 8.63 (d, J=8.0Hz, 1H), 8.02 (d, J=6.8Hz, 1H), 7.95 (d,
J=7.2Hz, 1H), 7.82 (t, J=8.0Hz, 1H), 7.38 (d, J=7.6Hz, 1H), 7.27 (t, J=7.2Hz, 1H), 7.16
(t, J=7.6Hz, 1H), 7.08-7.3-03 (m, 4H), 6.97-6.66 (m, 5H), 5.48 (s, 1H), 3.88 (q, J=6.8Hz,
2H), 1.23 (t, J=7.2Hz, 3H) .MS (ESI), m/z:M-441.0.
Embodiment 54
N- cyclopenta -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E54)
(N-cyclopentyl-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E54)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.72 (d, J=8.4Hz, 1H), 8.14 (d, J=6.8Hz, 1H), 8.09 (d,
J=7.6Hz, 1H), 7.95 (t, J=7.6Hz, 1H), 7.80 (d, J=7.2Hz, 1H), 7.26 (d, J=7.6Hz, 1H), 3.95
(q, J=7.2Hz, 2H), 3.44 (q, J=6.4Hz, 1H), 1.51-1.46 (m, 4H), 1.28-1.22 (m, 7H) .MS (ESI),
m/z:M-343.0.
Embodiment 55
N- (3- (tert-butyl group) phenyl) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E55)
(N-(3-(tert-butyl)phenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E55)
Synthetic method such as embodiment 10.
1H-NMR (400MHz, d-DMSO) δ 8.49 (d, J=8.4Hz, 1H), 8.13 (d, J=7.6Hz, 1H), 8.05 (d,
J=6.8Hz, 1H), 7.71 (t, J=7.6Hz, 1H), 7.08 (d, J=5.6Hz, 2H), 6.98 (s, 1H), 6.90 (s, 1H),
6.84 (d, J=7.2Hz, 2H), 3.94 (dd, J=14.2Hz, 7.4Hz, 2H), 1.34 (t, J=7.2Hz, 3H), 1.09 (s,
9H).MS(ESI),m/z:M-407.1
Embodiment 56
N- (2- (tert-butyl group) phenyl) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E56)
(N-(2-(tert-butyl)phenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E56)
1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonic acid chlorides synthetic method such as embodiment 1.
Take 1- ethyl-2-oxos -1,2- dihydrobenzo [cd] indoles -6- sulfonic acid chlorides (100mg, 0.338mmol), and 2-
(tert-butyl group) aniline (92mg, 0.617mmol) is dissolved in 3mL pyridines.Room temperature reaction overnight, after reaction completely, is washed, acetic acid second
Ester is extracted three times, merges organic layer, and 10% hydrochloric acid 50mL is washed once, and saturated sodium-chloride water solution is washed once, and anhydrous sodium sulfate is done
It is dry, column chromatography, obtain 50mg yellow greenish powder shape solids, yield 36%.
1H-NMR (400MHz, d-DMSO) δ 9.37 (s, 1H), 8.76 (d, J=8.4Hz, 1H), 8.21 (d, J=7.2Hz,
1H), 8.05 (d, J=7.6Hz, 1H), 7.94 (t, J=8.0Hz, 1H), 7.44 (d, J=8.0Hz, 1H), 7.32 (d, J=
7.6Hz, 1H), 7.15 (t, J=7.6Hz, 1H), 6.90 (t, J=7.6Hz, 1H), 6.36 (d, J=7.6Hz, 1H), 3.97 (q,
J=7.2Hz, 2H), 1.45 (s, 9H), 1.29 (t, J=7.2Hz, 3H) .MS (ESI), m/z:M-407.1
Embodiment 57
2- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) methyl benzoate (E57)
(2-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)benzoate)
(E57)
Synthetic method such as embodiment 56.
1H-NMR (400MHz, d-DMSO) δ 10.67 (s, 1H), 8.48 (d, J=8.4Hz, 1H), 8.22 (d, J=
7.6Hz, 1H), 8.10 (d, J=7.2Hz, 1H), 7.96 (t, J=7.6Hz, 1H), 7.75 (d, J=7.6Hz, 1H), 7.55-
7.48 (m, 2H), 7.27 (d, J=7.6Hz, 1H), 7.10 (t, J=7.2Hz, 1H), 3.88 (q, J=7.2Hz, 2H), 3.69
(s, 3H), 1.23 (t, J=7.2Hz, 3H) .MS (ESI), m/z:M-409.1
Embodiment 58
N- (2- benzoylphenyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E58)
(N-(2-benzoylphenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E58)
Synthetic method such as embodiment 56.
1H-NMR (400MHz, d-DMSO) δ 9.88 (s, 1H), 8.35 (d, J=7.6Hz, 1H), 7.91 (d, J=6.8Hz,
1H), 7.79 (d, J=7.6Hz, 1H), 7.72 (t, J=8.0Hz, 1H), 7.55 (t, J=7.6Hz, 1H), 7.47-7.42 (m,
2H), 7.28 (t, J=7.6Hz, 1H), 7.19-7.17 (m, 3H), 7.06 (d, J=7.6Hz, 1H), 6.97 (d, J=7.6Hz,
1H), 3.81 (q, J=6.8Hz, 2H), 1.21 (t, J=6.8Hz, 3H) .MS (ESI), m/z:M-455.0
Embodiment 59
N- (2- acetylphenyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E59)
(N-(2-acetylphenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E59)
Synthetic method such as embodiment 56.
1H-NMR (400MHz, d-DMSO) δ 11.67 (s, 1H), 8.44 (d, J=8.0Hz, 1H), 8.25 (d, J=
7.6Hz, 1H), 8.11 (d, J=7.2Hz, 1H), 7.95 (t, J=8.0Hz, 1H), 7.88 (d, J=8.0Hz, 1H), 7.50 (t,
J=7.6Hz, 1H), 7.42 (d, J=8.4Hz, 1H), 7.28 (d, J=7.6Hz, 1H), 7.11 (t, J=7.6Hz, 1H), 3.89
(q, J=7.2Hz, 2H), 2.48 (s, 3H), 1.23 (t, J=7.2Hz, 3H) .MS (ESI), m/z:M-393.0
Embodiment 60
1- ethyl-2-oxos-N- (pyridine -3- substitutions) -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E60)
1-ethyl-2-oxo-N-(pyridin-3-yl)-1,2-dihydrobenzo[cd]indole-6-
sulfonamide(E60)
Synthetic method such as embodiment 56.
1H-NMR (400MHz, d-DMSO) δ 10.83 (s, 1H), 8.66 (d, J=8.4Hz, 1H), 8.26 (s, 1H),
8.18-8.16 (m, 2H), 8.13 (d, J=6.8Hz, 1H), 7.94 (t, J=7.6Hz, 1H), 7.47 (d, J=8.4Hz, 1H),
7.28 (d, J=7.6Hz, 1H), 7.23-7.20 (m, 1H), 3.89 (q, J=6.8Hz, 2H), 1.23 (t, J=6.8Hz, 3H)
.MS(ESI),m/z:M-352.0
Embodiment 61
N- (3- acetylphenyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E61)
(N-(3-acetylphenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E61)
Synthetic method such as embodiment 56.
1H-NMR (400MHz, d-DMSO) δ 10.80 (s, 1H), 8.69 (d, J=8.0Hz, 1H), 8.18 (d, J=
7.6Hz, 1H), 8.10 (d, J=6.8Hz, 1H), 7.93 (t, J=7.6Hz, 1H), 7.59 (s, 1H), 7.54 (d, J=3.6Hz,
1H), 7.34-7.31 (m, 2H), 7.25 (d, J=7.6Hz, 1H), 3.86 (dd, J=13.8Hz, 7.0Hz, 2H), 2.43 (s,
3H), 1.20 (t, J=7.2Hz, 3H)
Embodiment 62
N- (3- bromo- 5- (trifluoromethyl) phenyl) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide
(E62)
(N-(3-bromo-5-(trifluoromethyl)phenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo
[cd]indole-6-sulfonamide)(E62)
Synthetic method such as embodiment 56.
1H-NMR (400MHz, d-DMSO) δ 11.28 (s, 1H), 8.64 (d, J=8.4Hz, 1H), 8.23 (d, J=
7.6Hz, 1H), 8.14 (d, J=7.2Hz, 1H), 7.97 (t, J=7.6Hz, 1H), 7.52 (s, 1H), 7.46 (s, 1H), 7.32
(t, J=7.6Hz, 2H), 3.89 (dd, J=14.0Hz, 6.8Hz, 2H), 1.22 (t, J=7.2Hz, 3H)
Embodiment 63
(E) -1- ethyl-2-oxos-N- (4- (phenyl-diazenyl) phenyl) -1,2- dihydrobenzos [cd] indoles -6- sulphurs
Acid amides (E63)
((E)-1-ethyl-2-oxo-N-(4-(phenyldiazenyl)phenyl)-1,2-dihydrobenzo[cd]
indole-6-sulfonamide)(E63)
Synthetic method such as embodiment 56.
1H-NMR (400MHz, d-DMSO) δ 11.10 (s, 1H), 8.74 (d, J=8.4Hz, 1H), 8.26 (d, J=
7.6Hz, 1H), 8.11 (d, J=7.2Hz, 1H), 7.95 (t, J=7.8Hz, 1H), 7.73 (t, J=9.0Hz, 4H), 7.50
(dd, J=14.6Hz, 7.0Hz, 3H), 7.27 (dd, J=8.0Hz, 4.0Hz, 3H), 3.86 (dd, J=14.0Hz, 6.8Hz,
2H), 1.20 (t, J=7.2Hz, 3H)
Embodiment 64
Ethyl 2- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) -3- (furans -2- bases)
Ethyl propionate (E64)
(ethyl2-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)-3-
(furan-2-yl)propanoate)(E64)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.58 (d, J=8.4Hz, 1H), 8.15 (d, J=7.6Hz, 1H), 8.10 (d,
J=6.8Hz, 1H), 7.83 (t, J=7.6Hz, 1H), 7.09 (s, 1H), 6.88 (d, J=7.6Hz, 1H), 6.09 (s, 1H),
5.91 (s, 1H), 5.37 (d, J=9.2Hz, 1H), 4.24-4.19 (m, 1H), 3.98 (q, J=7.2Hz, 2H), 3.85 (q, J=
7.2Hz, 2H), 3.04-3.00 (m, 1H), 1.57 (s, 1H), 1.38 (t, J=7.2Hz, 3H), 1.00 (t, J=7.2Hz, 3H)
.MS(ESI),m/z:M+443.1;M-441.1.
Embodiment 65
Ethyl -3- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide) -3- (5- methylfurans -2-
Base) ethyl propionate (E65)
(ethyl3-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)-3-
(5-methylfuran-2-yl)propanoate)(E65)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.61 (d, J=8.4Hz, 1H), 8.52 (d, J=8.8Hz, 1H), 8.11 (d,
J=6.8Hz, 1H), 7.97 (d, J=7.6Hz, 1H), 7.89 (d, J=7.2Hz, 1H), 7.21 (d, J=7.6Hz, 1H), 5.75
(s, 1H), 5.50 (s, 1H), 4.62 (q, J=7.6Hz, 1H), 3.95-3.85 (m, 4H), 2.70 (d, J=7.2Hz, 2H),
1.62 (s, 3H), 1.27 (t, J=6.8Hz, 3H), 1.06 (t, J=6.8Hz, 3H) .MS (ESI), m/z:M-455.1.
Embodiment 66
5- ((1- ethyl-2-oxos -1,2- dihydrobenzo [cd] indoles -6- sulfonamidos) methyl) thiophene -2-carboxylic acid
The tert-butyl ester (E66)
(ethyl5-((1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)
methyl)thiophene-2-carboxylate)(E66)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.64 (d, J=8.4Hz, 2H), 8.14 (d, J=6.8Hz, 1H), 8.04 (d,
J=7.6Hz, 1H), 7.93 (t, J=8.0Hz, 1H), 7.36 (d, J=8.0Hz, 1H), 7.22 (d, J=7.6Hz, 1H), 6.84
(d, J=7.6Hz, 1H), 4.28 (d, J=6.0Hz, 2H), 4.17 (q, J=6.8Hz, 2H), 3.92 (q, J=6.8Hz, 2H),
1.27-1.20(m,6H).MS(ESI),m/z:M-443.0.
Embodiment 67
2- (1- ethyl-2-oxo-1,2- dihydrobenzos [cd] indoles-6- sulfonamidos)-3- (furans-2-substitution) third
Sour (E67)
(2-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)-3-(furan-
2-yl)propanoic acid)(E67)
Ethyl 2- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) -3- (furans -2- bases)
Ethyl propionate synthetic method such as embodiment 64.
By ethyl 2- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) -3- (furans -2-
Base) ethyl propionate (130mg, 0.29mmol) dissolves with THF, and 2N sodium hydroxide solution 0.5mL are added dropwise in room temperature, react at room temperature
Night.Tetrahydrofuran is removed in rotation.Concentrated hydrochloric acid is added dropwise under ice bath, until without Precipitation, filters, obtains 106mg products, yield
88%.
1H-NMR (400MHz, d-DMSO) δ 8.48 (d, J=8.4Hz, 1H), 8.09 (d, J=7.2Hz, 1H), 7.88 (d,
J=7.2Hz, 1H), 7.68 (t, J=7.6Hz, 1H), 6.80-6.77 (m, 2H), 5.80 (s, 1H), 5.75 (s, 1H), 4.23
(s, 1H), 3.91-3.88 (m, 2H), 2.98-2.92 (m, 2H), 1.34 (t, J=7.6Hz, 3H) .MS (ESI), m/z:M-
413.0.
Embodiment 68
3- (1- ethyl-2-oxo-1,2- dihydrobenzos [cd] indoles-6- sulfonamidos)-3- (5- methylfurans-2-
Substitution) propionic acid (E68)
(3-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)-3-(5-
methylfuran-2-yl)propanoicacid)(E68)
Synthetic method such as embodiment 67.
1H-NMR (400MHz, d-DMSO) δ 8.59 (d, J=8.4Hz, 1H), 8.11-8.03 (m, 2H), 7.82 (t, J=
8.0Hz, 1H), 6.84 (d, J=7.6Hz, 1H), 5.73 (s, 1H), 5.49 (s, 1H), 4.77 (s, 1H), 4.00-3.94 (m,
2H), 3.48 (s, 1H), 2.93-2.76 (m, 2H), 1.38 (t, J=7.2Hz, 3H) .MS (ESI), m/z:M-427.0.
Embodiment 69
1- ((1- ethyl-2-oxo -1-1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) methyl) cyclopentane-carboxylic acid
Methyl esters (E68)
(ethyl1-((1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)
methyl)cyclopentane carboxylate)(E68)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.63 (d, J=8.4Hz, 1H), 8.17 (d, J=7.6Hz, 1H), 8.11 (d,
J=7.2Hz, 1H), 7.86 (t, J=8.0Hz, 1H), 6.93 (d, J=7.6Hz, 1H), 5.36 (t, J=6.8Hz, 1H),
4.04-3.96 (m, 4H), 2.92 (d, J=7.2Hz, 2H), 1.93-1.89 (m, 2H), 1.71 (s, 2H), 1.58-1.54 (m,
6H), 1.39 (t, J=7.2Hz, 3H), 1.16 (t, J=7.2Hz, 3H) .MS (ESI), m/z:M-429.0.
Embodiment 70
1- ethyls-N- (isoquinolin-8-substitution)-2- oxo-1,2- dihydrobenzos [cd] indoles-6- sulfonamide (E70)
(1-ethyl-N-(isoquinolin-7-yl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E70)
Synthetic method such as embodiment 56.
1H-NMR (400MHz, d-DMSO) δ 11.04 (s, 1H), 9.15 (s, 1H), 8.74 (d, J=8.4Hz, 1H), 8.32
(d, J=5.6Hz, 1H), 8.29 (d, J=8.0Hz, 1H), 8.09 (d, J=7.2Hz, 1H), 7.93 (t, J=7.6Hz, 1H),
7.78 (d, J=8.8Hz, 1H), 7.72 (s, 1H), 7.62 (d, J=6.0Hz, 1H), 7.47 (d, J=9.2Hz, 1H), 7.23
(d, J=8.0Hz, 1H), 3.84 (dd, J=14.0Hz, J=7.2Hz, 2H), 1.18 (t, J=7.20Hz, 3H)
Embodiment 71
Ethyl 4- (3,5- 3,5-dimethylphenyls) -3- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfenyls
Amino) ethyl butyrate (E71)
(ethyl 4-(3,5-dimethylphenyl)-3-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]
indole-6-sulfonamido)butanoate)(E71)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.54 (d, J=8.0Hz, 1H), 8.06 (d, J=7.2Hz, 1H), 7.88 (d,
J=7.6Hz, 1H), 7.79 (t, J=8.0Hz, 1H), 6.66 (t, J=8.0Hz, 1H), 6.59 (s, 1H), 6.34 (d, J=
7.6Hz, 1H), 5.80 (d, J=7.2Hz, 1H), 4.96 (q, J=6.4Hz, 1H), 4.01-3.89 (m, 4H), 2.69 (dd, J=
6.4Hz, 2H), 2.06 (d, J=9.6Hz, 6H), 1.56 (s, 2H), 1.35 (t, J=7.2Hz, 3H), 1.13 (t, J=7.2Hz,
3H).
Embodiment 72
Ethyl 2- ((1- ethyl-2-oxo -1-1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) methyl) benzoic acid
Methyl esters
(E72)
(ethyl 2-((1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)
methyl)benzoate)(E72)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.46 (d, J=8.4Hz, 1H), 8.02 (t, J=7.2Hz, 2H), 7.72 (t,
J=8.0Hz, 1H), 7.58 (d, J=8.0Hz, 1H), 7.18 (t, J=7.2Hz, 1H), 7.10-7.07 (m, 2H), 6.74 (d, J
=7.6Hz, 1H), 6.27 (t, J=6.8Hz, 1H), 4.39 (d, J=7.2Hz, 2H), 4.19 (q, J=7.6Hz, 2H), 3.95
(q, J=7.6Hz, 2H), 1.39 (t, J=7.2Hz, 3H), 1.30 (t, J=7.2Hz, 3H)
Embodiment 73
3- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide) ethyl butyrate (E73)
(ethyl 3-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)
heptanoate)(E73)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.62 (d, J=8.4Hz, 1H), 8.20 (d, J=7.6Hz, 1H), 8.10 (d,
J=7.2Hz, 1H), 7.83 (t, J=7.6Hz, 1H), 6.92 (d, J=7.6Hz, 1H), 5.40 (d, J=9.2Hz, 1H),
4.01-3.90 (m, 4H), 3.50 (d, J=4.4Hz, 1H), 2.36 (s, 2H), 1.49-1.43 (m, 1H), 1.39 (t, J=
7.2Hz, 4H), 1.14 (t, J=5.6Hz, 3H), 1.15-1.14 (m, 3H), 1.12-0.93 (m, 1H), 0.58 (t, J=
7.2Hz,3H).
Embodiment 74
2- ethyls -2- ((1- ethyl-2-oxos -1,2- dihydrobenzo [cd] indoles -6- sulfonamidos) methyl) butyric acid
(E74)
(2-ethyl-2-((1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)
methyl)butanoic acid)(E74)
Synthetic method such as embodiment 67.
1H-NMR (400MHz, d-DMSO) δ 8.78 (d, J=8.4Hz, 1H), 8.14 (d, J=7.2Hz, 1H), 7.95 (d,
J=7.6Hz, 1H), 7.65 (s, 1H), 7.34 (d, J=7.6Hz, 1H), 3.95 (q, J=7.2Hz, 2H), 2.85 (s, 2H),
1.50-1.38 (m, 4H), 1.27 (t, J=6.8Hz, 3H), 1.21 (s, 1H), 0.58 (t, J=7.2Hz, 4H)
Embodiment 75
5- ((1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) methyl) thiophene-2-carboxylic acid
(E75)
(5-((1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)methyl)
thiophene-2-carboxylic acid)(E75)
Synthetic method such as embodiment 67.
1H-NMR (400MHz, d-DMSO) δ 8.64-8.608.64 (m, 2H), 8.11 (d, J=6.8Hz, 1H), 8.04 (d,
J=7.2Hz, 1H), 7.93 (t, J=7.6Hz, 1H), 7.32 (d, J=7.2Hz, 1H), 7.22 (d, J=7.6Hz, 2H), 6.81
(s, 1H), 4.26 (d, J=5.6Hz, 2H), 3.92 (t, J=6.0Hz, 3H), 1.28-0.22 (m, 5H)
Embodiment 76
1- ((1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) methyl) cyclopentane-carboxylic acid
(E76)
(1-((1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)methyl)
cyclopentanecarboxylic acid)(E76)
Synthetic method such as embodiment 67.
1H-NMR (400MHz, d-DMSO) δ 8.63 (d, J=8.4Hz, 1H), 8.17 (d, J=7.6Hz, 1H), 8.11 (d,
J=7.2Hz, 1H), 7.86 (t, J=8.0Hz, 1H), 6.93 (d, J=7.6Hz, 1H), 5.36 (t, J=6.8Hz, 1H), 3.92
(m,3H),2.83(s,2H),1.81(m,2H),1.45(m,6H),1.25(m,4H).
Embodiment 77
N- (the chloro- 4- luorobenzyls of 3-) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E77)
(N-(3-chloro-4-fluorobenzyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]
indole-6-sulfonamide)(E77)
Synthetic method such as embodiment 1.
1H-NMR(400MHz,CDCl3) δ 8.60 (d, J=8.4Hz, 1H), 8.09 (t, J=7.2Hz, 2H), 7.82 (t, J
=7.8Hz, 1H), 6.98 (d, J=7.2Hz, 1H), 6.94 (d, J=4.4Hz, 1H), 6.88-6.83 (m, 2H), 4.10 (d, J
=6.0Hz, 2H), 3.97 (dd, J=14.4Hz, 7.2Hz, 2H), 1.38 (t, J=7.2Hz, 3H)
Embodiment 78
4- (3,5- 3,5-dimethylphenyls) -3- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfenyl ammonia
Base) butyric acid (E78)
(4-(3,5-dimethylphenyl)-3-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-
6-sulfonamido)butanoic acid)(E78)
Synthetic method such as embodiment 67.
1H-NMR (400MHz, d-DMSO) δ 8.53 (d, J=8.4Hz, 1H), 8.04 (d, J=6.8Hz, 1H), 7.85-
7.79 (m, 2H), 6.98 (d, J=7.6Hz, 1H), 6.67 (d, J=7.6Hz, 1H), 6.35 (s, 1H), 6.35 (d, J=
7.6Hz, 1H), 6.02 (d, J=7.6Hz, 1H), 4.80 (t, J=7.2Hz, 2H), 3.85 (s, 3H), 1.83 (s, 3H), 1.28-
1.22(m,7H).
Embodiment 79
2- ((1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) methyl) benzoic acid (E79)
(2-((1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)methyl)
benzoic acid)(E79)
Synthetic method such as embodiment 67.
1H-NMR (400MHz, d-DMSO) δ 8.65 (d, J=8.4Hz, 1H), 8.31 (s, 1H), 8.15 (d, J=6.8Hz,
1H), 8.02 (d, J=7.2Hz, 1H), 7.91 (t, J=8.0Hz, 1H), 7.69 (d, J=7.6Hz, 1H), 7.42 (d, J=
7.6Hz, 1H), 7.31 (t, J=7.2Hz, 1H), 7.23-7.18 (m, 2H), 4.40 (d, J=5.6Hz, 2H), 3.92 (d, J=
7.2Hz, 2H), 1.29 (t, J=6.8Hz, 3H)
Embodiment 80
N- (1- acetylindole -5- bases) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide
(E80)
(N-(1-acetylindolin-5-yl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide)(E80)
Synthetic method such as embodiment 56.
1H-NMR (400MHz, d-DMSO) δ 10.31 (s, 1H), 8.70 (d, J=8.4Hz, 1H), 8.13 (d, J=
7.2Hz, 1H), 8.07 (d, J=7.6Hz, 1H), 7.92 (d, J=8.0Hz, 1H), 7.77 (d, J=7.2Hz, 1H), 7.91 (t,
J=8.4Hz, 1H), 7.25 (d, J=7.6Hz, 1H), 6.91 (s, 1H), 6.77 (d, J=8.8Hz, 1H), 3.96 (t, J=
8.4Hz, 2H), 3.88 (q, J=6.8Hz, 2H), 2.97 (t, J=8.4Hz, 2H), 2.05 (s, 1H), 1.24 (t, J=7.2Hz,
3H).
Embodiment 81
3- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) enanthic acid (E81)
(3-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)heptanoic
acid)(E81)
Synthetic method such as embodiment 67.
1H-NMR (400MHz, d-DMSO) δ 8.69 (d, J=8.4Hz, 1H), 8.14 (d, J=6.8Hz, 1H), 8.07 (d,
J=7.6Hz, 1H), 7.93 (t, J=7.2Hz, 1H), 7.28 (d, J=7.2Hz, 1H), 3.95 (d, J=6.8Hz, 2H),
2.26-2.18 (m, 2H), 1.27-1.20 (m, 6H), 0.79-0.63 (m, 4H), 0.34-0.31 (t, J=6.0Hz, 3H)
Embodiment 82
1- ethyls -6- ((4- (pyridine -2- ylmethyls) piperazine -1- substitutions) sulfonyl) benzo [cd] indoles -2 (1H) -one
(E82)
(1-ethyl-6-((4-(pyridin-2-ylmethyl)piperazin-1-yl)sulfonyl)benzo[cd]
indol-2(1H)-one)(E82)
Synthetic method such as embodiment 1.
1H-NMR (400MHz, d-DMSO) δ 8.65 (d, J=8.4Hz, 1H), 8.41 (d, J=4.4Hz, 1H), 8.18 (d,
J=7.2Hz, 1H), 8.07 (d, J=7.6Hz, 1H), 7.94 (t, J=8.0Hz, 1H), 7.63 (t, J=7.6Hz, 1H), 7.38
(d, J=7.6Hz, 1H), 7.25 (d, J=8.0Hz, 1H), 7.16 (t, J=5.6Hz, 1H), 3.95 (q, J=7.2Hz, 2H),
3.54 (s, 2H), 3.01 (s, 4H), 2.43 (s, 4H), 1.29 (t, J=6.8Hz, 3H)
Embodiment 83
1- ethyl-2-oxos-N- (3,4,5- trimethoxyphenyls) -1,2- dihydrobenzos [cd] indoles -6- sulfonamide
(E83)
1-ethyl-2-oxo-N-(3,4,5-trimethoxyphenyl)-1,2-dihydrobenzo[cd]indole-
6-sulfonamide(E83)
Synthetic method such as embodiment 67.
1HNMR(400MHz,CDCl3) δ 8.52 (d, J=8.4Hz, 1H), 8.09 (d, J=7.2Hz, 2H), 7.79 (d, J=
7.6Hz, 1H), 6.87-6.85 (m, 1H), 6.61 (d, J=8.4Hz, 3H), 6.68 (d, J=8.8Hz, 2H), 3.95 (q, J=
7.2Hz, 2H), 3.72 (s, 3H), 3.62 (s, 6H), 1.31 (t, J=7.2Hz, 3H)
Embodiment 84
1- ethyls-N- (4- methoxyphenyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E84)
1-ethyl-N-(4-methoxyphenyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide(E84)
Synthetic method such as embodiment 67.
1H NMR(400MHz,CDCl3) δ 8.48 (d, J=8.4Hz, 1H), 8.09 (d, J=7.2Hz, 1H), 8.01 (d, J
=7.6Hz, 1H), 7.85-7.63 (m, 1H), 6.87-6.81 (m, 3H), 6.68 (d, J=8.8Hz, 2H), 6.47 (s, 1H),
3.95 (q, J=7.2Hz, 2H), 3.71 (s, 3H), 1.36 (t, J=7.2Hz, 3H)
Embodiment 85
N- (3,4- Dimethoxyphenyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E85)
N-(3,4-dimethoxyphenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide(E85)
Synthetic method such as embodiment 1.
1HNMR(400MHz,CDCl3) δ 8.52 (d, J=8.4Hz, 1H), 8.07 (d, J=7.2Hz, 1H), 7.97 (d, J=
7.6Hz, 1H), 7.76 (t, J=7.6Hz, 1H), 7.42 (d, J=8.8Hz, 1H), 6.79 (d, J=7.6Hz, 1H), 6.68 (s,
1H), 6.43 (d, J=8.8Hz, 1H), 6.08 (d, J=6.8Hz, 1H), 3.94 (q, J=7.2Hz, 2H), 3.72 (s, 3H),
3.04 (s, 3H), 1.35 (t, J=7.2Hz, 3H)
Embodiment 86
1- ethyls-N- (3- methoxyphenyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E86)
1-ethyl-N-(3-methoxyphenyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide(E86)
Synthetic method such as embodiment 67.
1HNMR(400MHz,CDCl3) δ 8.57 (d, J=8.4Hz, 1H), 8.15 (d, J=7.6Hz, 1H), 8.07 (d, J=
7.2Hz, 1H), 7.77 (t, J=7.6Hz, 1H), 7.04 (t, J=8.0Hz, 1H), 6.97 (s, 1H), 6.85 (d, J=7.6Hz,
1H), 6.74-6.58 (m, 2H), 6.54 (d, J=8.0Hz, 1H), 3.94 (q, J=7.2Hz, 2H), 3.68 (s, 3H), 1.35
(t, J=7.2Hz, 3H)
Embodiment 87
N- (3,5- Dimethoxyphenyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E87)
N-(3,5-dimethoxyphenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide(E87)
Synthetic method such as embodiment 67.
1HNMR(400MHz,CDCl3) δ 8.59 (d, J=8.4Hz, 1H), 8.17 (d, J=7.6Hz, 1H), 8.07 (d, J=
7.2Hz, 1H), 7.90-7.70 (m, 1H), 6.92 (s, 1H), 6.86 (d, J=7.6Hz, 1H), 6.19 (s, 2H), 6.14 (s,
1H), 3.95 (q, J=7.2Hz, 2H), 3.64 (s, 6H), 1.36 (t, J=7.2Hz, 3H)
Embodiment 88
N- (4- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) phenyl) acetamide
(E88)
N-(4-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)phenyl)
acetamide(E88)
Synthetic method such as embodiment 67.
1H NMR (400MHz, d-DMSO) δ 10.33 (s, 1H), 9.79 (s, 1H), 8.68 (d, J=8.0Hz, 1H), 8.10
(dd, J=14.4,6.8Hz, 2H), 7.92 (t, J=7.2Hz, 1H), 7.34 (d, J=7.6Hz, 2H), 7.23 (d, J=
7.6Hz, 1H), 6.94 (d, J=7.6Hz, 2H), 3.88 (d, J=6.8Hz, 2H), 1.95 (s, 3H), 1.23 (t, J=7.2Hz,
3H).
Embodiment 89
2- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) benzoic acid (E89)
2-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)benzoic
acid(E89)
Synthetic method such as embodiment 67.
1H NMR (400MHz, d-DMSO) δ 11.96 (s, 1H), 8.52 (d, J=8.4Hz, 1H), 8.26 (d, J=
7.6Hz, 1H), 8.13 (d, J=7.2Hz, 1H), 8.02-7.84 (m, 1H), 7.80 (d, J=7.2Hz, 1H), 7.63-7.41
(m, 2H), 7.28 (d, J=7.6Hz, 1H), 7.02 (t, J=7.6Hz, 1H), 3.89 (q, J=7.2Hz, 2H), 1.23 (t, J=
7.2Hz,3H).
Embodiment 90
1- ethyls-N- (4- fluorophenyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide (E90)
1-ethyl-N-(4-fluorophenyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-
sulfonamide(E90)
Synthetic method such as embodiment 67.
1HNMR (400MHz, d-DMSO) δ 10.48 (s, 1H), 8.64 (d, J=8.4Hz, 1H), 8.13-8.07 (m, 2H),
8.00-7.79 (m, 1H), 7.25 (d, J=7.6Hz, 1H), 7.17-6.83 (m, 4H), 3.89 (q, J=7.2Hz, 2H), 1.25
(t, J=7.2Hz, 3H)
Embodiment 91
N- ((1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- bases) sulfonyl)-N- (4- methoxyphenyls)
Pyrazinamide (E91)
N-((1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfonyl)-N-(4-
methoxyphenyl)isonicotina mide(E91)
The synthesis side of 1- ethyls-N- (4- methoxyphenyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide
Method is referring to embodiment 83.
By 1- ethyls-N- (4- methoxyphenyls) -2- oxos -1,2- dihydrobenzo [cd] indoles -6- sulfonamide (100mg,
0.26mmol) dissolved with dichloromethane, room temperature add isonicotinic acid (34mg, 0.28mmol), HATU (148mg, 380mmol) and
DIPEA (0.5mL), room temperature reaction is overnight.Washing, ethyl acetate extract three times, are associated with several layers of, saturated common salt washing one time,
Anhydrous sodium sulfate drying.Column chromatography:Petroleum ether:Ethyl acetate=1:1, obtain product 23mg, yield 18%.1H NMR(400MHz,
CDCl3) δ 8.53 (d, J=7.6Hz, 1H), 8.47 (s, 2H), 8.12 (d, J=8.4Hz, 1H), 8.06 (d, J=7.2Hz,
1H), 7.63 (t, J=7.6Hz, 1H), 7.16 (d, J=4.4Hz, 2H), 7.04 (t, J=7.6Hz, 3H), 6.77 (d, J=
8.4Hz, 2H), 4.03 (q, J=7.2Hz, 2H), 3.78 (s, 3H), 1.41 (t, J=7.2Hz, 3H)
Embodiment 92
External activity is tested:The present invention is using AlphaScreen detection techniques checking the compounds of this invention to ROR γ eggs
White rejection ability.
1st, experiment purpose
Determine inhibitory activity of the compounds of this invention to ROR γ albumen.
2nd, experiment material
Destination protein ROR γ 100nM;Test buffer (10 ×) MOPS (500mM), CHAPS (0.5mM), NaF
(500mM), BSA (1mg/mL), PH7.4;The μ g/mL of donor microballon 50 in kit, the μ g/mL of Acceptor beads 50;ROR γ excitements altogether
The factor, small peptide SRC1-4 (QKPTSGPQTPQAQQKSLLQQLLTE) 20nM;In 150 μ L reaction systems:RORγ:15 μ L, experiment
Buffer solution:15 μ L, deionized water:15 μ L, micromolecular compound:15 μ L, donor microballon:15 μ L, Acceptor beads:15μL;It is positive
Inhibitor:T1317,SR2211,UA,Digoxin.
3rd, experimental method
Lucifuge is incubated 2 hours, is transferred to 384 orifice plates, and 40 μ L liquid are shifted per hole, by multi-functional detection ELIASA, is swashed
Send out wavelength:680nM, launch wavelength 520-620nM detect reading.
4th, experimental result
The compounds of this invention E1-E82 is as shown in Figure 1 to the inhibitory activity data of ROR γ albumen.
Active IC of the preferably compound to the inhibitory activity of ROR γ albumen50Numerical value is as shown in following table one:
Table one:Active IC of the preferably compound to the inhibitory activity of ROR γ albumen50
Test result indicates that:The compounds of this invention has extraordinary inhibitory action, particularly compound to ROR γ albumen
E10, E63 are suitable with comparison medicine to the inhibitory activity of ROR γ albumen.
Embodiment 93
External activity is tested:The present invention verifies the rejection ability of the compounds of this invention using Luciferase detection techniques.
1st, experiment purpose
Determine the compounds of this invention inhibitory activity horizontal to nuclear receptor ROR gamma cellses.
2nd, experiment material
People's renal epithelial cell system 293T cells;DMEM culture mediums containing 10% hyclone;96 orifice plate transparent panels;Double reports
Accuse gene detecting kit;Opti-MEM reagents;The transfection reagents of Lipo-fectamine 2000;Recombinant plasmid:Gal4-RORγ
LBD:25ng, Full-length-ROR γ:25ng, pG5-luc, Renilla;Positive inhibitor:T1317,SR2211,UA.
3rd, experimental method
People's renal epithelial cell system 293T cells, with the DMEM medium cultures containing 10% hyclone.The day before transfection
By cell prepare with 96 orifice plates in, cell density 1x104Individual/hole.Adherent growth is transiently transfected after 24 hours, using double
The method of reporter gene cotransfection, transfection reagent Lipo-fectamine2000, transfection is diluted respectively with Opti-MEM reagents
Reagent and plasmid.Gal4-ROR γ LBD are per hole 25ng;PG5-luc genes are per hole 25ng;Renilla is per hole 5ng, cotransfection 24
The compound of various concentrations is added after hour, after being incubated 24 hours, using the double reporter gene detection kits of Luciferase, inspection
Survey luminous signal, each 3 multiple holes of sample.
People's renal epithelial cell system 293T cells, with the DMEM medium cultures containing 10% hyclone.The day before transfection
By cell prepare with 96 orifice plates in, cell density 1x104Individual/hole.Adherent growth is transiently transfected after 24 hours, using double
The method of reporter gene cotransfection, transfection reagent Lipo-fectamine2000, transfection is diluted respectively with Opti-MEM reagents
Reagent and plasmid.Full-length-ROR γ are per hole 25ng;PG5-luc genes are per hole 25ng;Renilla is per hole 5ng, corotation
Dye adds the compound of various concentrations after 24 hours, after being incubated 24 hours, using the double reporter gene detection reagents of Luciferase
Box, detect luminous signal, each 3 multiple holes of sample.
Inhibitory activity horizontal to ROR gamma cellses the compounds of this invention E1-E82 is illustrated in fig. 2 shown below.
The IC of the active preferably compound inhibitory activity horizontal to ROR gamma cellses50Numerical value is as shown in following table two:
NT:Do not test
Table two:The IC of the active preferably compound inhibitory activity horizontal to ROR gamma cellses50
Test result indicates that:The compounds of this invention finds that there is extraordinary suppression to make for it to the horizontal checkout of ROR gamma cellses
With particularly compound E11, E17, E70 is more preferable than comparison medicine activity to the horizontal inhibitory activity of ROR gamma cellses.Chemical combination simultaneously
Thing E19, E45, E63 are suitable with comparison medicine inhibitory activity.
2- oxos -1,2- dihydrobenzos [cd] indoles -6- sulfamide compounds of the present invention and its pharmaceutically may be used
The salt of receiving, it can effectively suppress the protein active and cytoactive of vitamin A acid orphan's nuclear receptor γ hypotypes, particularly compound
E10, E11, E17, E19, E45, E56, E63, E70 are suitable with positive compound, and contrast positive compound has Stability Analysis of Structures
With easy the advantages of preparing.Simultaneously it can be seen that reactive compound is structurally characterized in that:1)R1For ethyl;2)R2,R3Mainly connect
Have the phenyl ring compared with large-substituent, these substituents because on phenyl ring position it is changeable, and various structures, it can be seen that this kind of compound
Mother nucleus structure to activity keep tool play a very important role.Fully showing that this kind of compound has herein turns into treatment inflammation disease
Disease and the potentiality of immunologic derangement and treatment of cancer etc..
Embodiment described above only expresses the several embodiments of the present invention, and its description is more specific and detailed, but simultaneously
Therefore the limitation to the scope of the claims of the present invention can not be interpreted as.It should be pointed out that for one of ordinary skill in the art
For, without departing from the inventive concept of the premise, various modifications and improvements can be made, these belong to the guarantor of the present invention
Protect scope.Therefore, the protection domain of patent of the present invention should be determined by the appended claims.
Claims (5)
1. compound or its pharmaceutically acceptable salt, racemic modification with formula (I) architectural feature, it is characterised in that
R1It is selected from:
Ethyl;
R2, R3It is selected from:
1)H;
2) by 1 or 2 or 3 formoxyls, the tert-butyl group, morpholinyl, phenyl-diazenyl, phenoxy group, formamido, amino first
The phenyl of tert-butyl acrylate substitution;
3) quinoline, isoquinolin, benzothiazole, it optionally can substitute by 0 or 1 ethyoxyl;
R2And R3It is asynchronously H;
Or R2, R3In one be selected from H, another is selected from phenyl of 3,4 methoxy substitutions.
2. compound or its pharmaceutically acceptable salt, racemic modification with formula (I) architectural feature, it is characterised in that described
Compound selection is as follows:
1- ethyl-2-oxos-N- (2- oxos -2- (pyrrolidines -1- substitutions) ethyl) -1,2- dihydrobenzos [cd] indoles -6- sulphurs
Acid amides,
N- ((1- Acetylpiperidins -4- substitutions) methyl) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulphonyl
Amine,
1- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) cyclohexane carboxamide,
1- ethyls-N- (2- (ethylsulfonyl) ethyl) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
N- ((3,5- dimethyl -4,5- dihydro-isoxazoles -5- substitutions) methyl) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd]
Indoles -6- sulfonamide,
1- ethyls-N- ((3- isopropyl -4,5- dihydro-isoxazoles -5- substitutions) methyl) -2- oxo -1,2- dihydrobenzos [cd] Yin
Diindyl -6- sulfonamide,
N- ((3,5- dimethyl -4,5- dihydro-isoxazole -5- bases) methyl) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] Yin
Diindyl -6- sulfonamide,
1- ethyls-N- ((5- methyl isophthalic acid H- indazole -3- bases) methyl) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulphonyl
Amine,
1- ethyls-N- ((4- methyl-6- (trifluoromethyl) pyrimidine-2-substitution) methyl)-2- oxo-1,2- dihydrobenzos [cd] Yin
Diindyl -6- sulfonamide,
The tert-butyl group (3- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) phenyl) carbamic acid uncle
Butyl ester,
N- (3,4- Dimethoxyphenyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide
1- ethyls-N- ((1- methyl -5- (trifluoromethyl) -1H- benzo [d] imidazoles -2- substitutions) methyl) -2- oxos -1,2- two
Hydrogen benzo [cd] indoles -6- sulfonamide,
1- ethyls-N- ((the fluoro- 1H- indoles -2- substitutions of 5-) methyl) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulphonyl
Amine,
1- ethyls-N- ((5- methoxyl group -1H- indoles -2- substitutions) methyl) -2- oxo base -1,2- dihydrobenzo [cd] indoles -6-
Sulfonamide,
1- ethyls-N- (3- methyl isophthalic acids-(pyridine -3- substitutions) butyl) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulphonyl
Amine,
1-N- (4- chloro- 3- (trifluoromethyl) phenyl) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
N- (4- acetylphenyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide
N- (benzo [d] [1,3] dioxole-5-substituent methyl)-1- ethyl-2-oxo-1,2- dihydrobenzos [cd]
Indoles -6- sulfonamide,
1- ethyls-N- (4- morphlinophenyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
1- ethyls-N- (4- methyl-benzyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
N- (4- (tert-butyl group) benzyl) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
1- ethyls-N- (4- fluorobenzene ethyl) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
N- ((2,2- dimethyl -1,3- dioxolanes -4- bases) methyl) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] Yin
Diindyl -6- sulfonamide,
1- ethyls-N- (2- morpholinoethyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
1- ethyls-N- (4- methoxy-benzyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
1- ethyls-N- (3- methyl-benzyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
N- ((6- chloropyridines-3-substitution) methyl)-1- ethyl-2-oxo-1,2- dihydrobenzos [cd] indoles-6- sulfonamide,
1- ethyls-N- (the fluoro- 4- methyl-benzyls of 3-) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
N- (the chloro- 6- luorobenzyls of 2-) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
N- (4- chlorobenzene ethyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
1- ethyls-N- (4- luorobenzyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
N- (2- chlorobenzyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
1- ethyls-N- (2- luorobenzyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
N- (1- acetyl group -4- substitutions) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
1- ethyls-N- (2- methyl-benzyls) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
1- ethyls-6- ((4- (pyridin-4-yl methyl) piperazine-1-substitution) sulfonyl) benzo [cd] indoles-2 (1H) -one,
N- (2- chlorobenzene ethyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
1- ethyl-2-oxos-N- (4- (trifluoromethyl) benzyl) -1,2- dihydrobenzos [cd] indoles -6- sulfonamide
N- (double (trifluoromethyl) benzyls of 3,5-) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
1- ethyls-N- (4- fluoro- 3- (trifluoromethyl) benzyl) -2- oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
N- (the bromo- 2- luorobenzyls of 4-) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
1- ethyl-2-oxos-N- (3,4,5- trifluoro-benzyls) -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
N- (2,5- dichloro benzyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
N- (2,4 difluorobenzene base) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
1- ethyls-N- ((1- ethyl-2-oxo-1-1,2- dihydrobenzos [cd] indoles-6-substitution) sulfonyl)-N- (fluoro- 2- of 5-
Aminomethyl phenyl) -2- oxo 1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
N- (1- benzyl piepridines-4-substitution)-1- ethyl-2-oxo-1,2- dihydrobenzos [cd] indoles-6- sulfonamide,
6- ((4- (2- chlorphenyls) piperazine-1-substitution) sulfonyl)-1- ethyls benzo [cd] indoles-2 (1H) -one,
N- ([1,1'- biphenyl]-3-substitution)-1- ethyl-2-oxo-1,2- dihydrobenzos [cd] indoles-6- sulfonamide,
Tert-butyl group 4- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) tertiary fourth of piperidines -1- formic acid
Ester,
N- (3- chlorobenzene ethyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
N- benzhydryl -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
N- (3- (tert-butyl group) phenyl) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
N- (2- (tert-butyl group) phenyl) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
2- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) methyl benzoate,
N- (2- benzoylphenyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
N- (2- acetylphenyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
1- ethyl-2-oxos-N- (pyridine-3-substitution)-1,2- dihydrobenzos [cd] indoles-6- sulfonamide,
N- (3- acetylphenyls) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
N- (3- bromo- 5- (trifluoromethyl) phenyl) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
(E) -1- ethyl-2-oxos-N- (4- (phenyl-diazenyl) phenyl) -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
Ethyl 2- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) -3- (furans -2- bases) propionic acid
Ethyl ester,
Ethyl -3- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide) -3- (5- methylfuran -2- bases)
Ethyl propionate,
5- ((1- ethyl-2-oxos -1,2- dihydrobenzo [cd] indoles -6- sulfonamidos) methyl) tertiary fourth of thiophene -2-carboxylic acid
Ester,
2- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) -3- (furans -2- substitutions) propionic acid,
3- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) -3- (5- methylfurans -2- substitutions)
Propionic acid,
1- ((1- ethyl-2-oxo -1-1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) methyl) cyclopentane-carboxylic acid first
Ester,
1- ethyls-N- (isoquinolin-8-substitution)-2- oxo-1,2- dihydrobenzos [cd] indoles-6- sulfonamide,
Ethyl 4- (3,5- 3,5-dimethylphenyls) -3- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfenyl ammonia
Base) ethyl butyrate,
Ethyl 2- ((1- ethyl-2-oxo -1-1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) methyl) benzoic acid first
Ester,
3- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide) ethyl butyrate,
2- ethyls -2- ((1- ethyl-2-oxos -1,2- dihydrobenzo [cd] indoles -6- sulfonamidos) methyl) butyric acid,
5- ((1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) methyl) thiophene-2-carboxylic acid,
1- ((1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) methyl) cyclopentane-carboxylic acid,
N- (the chloro- 4- luorobenzyls of 3-) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
4- (3,5- 3,5-dimethylphenyls) -3- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) fourth
Acid,
2- ((1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) methyl) benzoic acid,
N- (1- acetylindole -5- bases) -1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamide,
3- (1- ethyl-2-oxo -1,2- dihydrobenzos [cd] indoles -6- sulfonamidos) enanthic acid,
1- ethyls -6- ((4- (pyridine -2- ylmethyls) piperazine -1- substitutions) sulfonyl) benzo [cd] indoles -2 (1H) -one.
3. compound described in claim 1-2 or its pharmaceutically acceptable salt, racemic modification are preparing ROR γ acceptor inhibitors
In application.
4. compound described in claim 1-2 or its pharmaceutically acceptable salt, racemic modification exist as ROR γ acceptor inhibitors
Prepare treatment encephalomyelitis, Collagen-induced Arthritis, multiple sclerosis, rheumatic arthritis, psoriasis, clone disease,
Application in the medicine of asthma and prostate cancer.
5. a kind of pharmaceutical composition as ROR γ acceptor inhibitors, it is characterised in that its active ingredient includes having the right to seek 1-
2 compounds or its pharmaceutically acceptable salt, racemic modification.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410821535.5A CN104530014B (en) | 2013-12-25 | 2014-12-24 | Sulfamide compound of the dihydrobenzo of 2 oxo 1,2 [cd] indoles 6 and combinations thereof and application |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013107295610 | 2013-12-25 | ||
CN201310729561 | 2013-12-25 | ||
CN201410821535.5A CN104530014B (en) | 2013-12-25 | 2014-12-24 | Sulfamide compound of the dihydrobenzo of 2 oxo 1,2 [cd] indoles 6 and combinations thereof and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104530014A CN104530014A (en) | 2015-04-22 |
CN104530014B true CN104530014B (en) | 2018-03-20 |
Family
ID=52845685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410821535.5A Active CN104530014B (en) | 2013-12-25 | 2014-12-24 | Sulfamide compound of the dihydrobenzo of 2 oxo 1,2 [cd] indoles 6 and combinations thereof and application |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN104530014B (en) |
WO (1) | WO2015096771A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105985282B (en) * | 2015-01-28 | 2020-12-08 | 中国科学院广州生物医药与健康研究院 | 2-oxo-1, 2-dihydrobenzo [ cd ] indole compound and application thereof |
EP3268087A4 (en) | 2015-03-12 | 2018-08-29 | The Regents of the University of California | METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS |
CN114790169A (en) * | 2016-01-29 | 2022-07-26 | 中国科学院广州生物医药与健康研究院 | Tetrahydroquinoline related bicyclic compound and application thereof |
WO2021047406A1 (en) * | 2019-09-10 | 2021-03-18 | 四川科伦博泰生物医药股份有限公司 | Tricyclic compound, pharmaceutical composition containing same, preparation method therefor and use thereof |
CN113912563A (en) * | 2020-07-10 | 2022-01-11 | 中国科学院广州生物医药与健康研究院 | Benzo five-membered nitrogen heterocyclic compound and application thereof |
CN111995563A (en) * | 2020-08-04 | 2020-11-27 | 常州大学 | Inhibitors of phosphodiesterase PDE2 activity |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2606716A1 (en) * | 1975-02-21 | 1976-09-02 | Ciba Geigy Ag | NEW DISPERSION COLORS |
CN1863785A (en) * | 2003-08-08 | 2006-11-15 | 沃泰克斯药物股份有限公司 | Compositions useful as inhibitors of voltage-gated sodium channels |
WO2009016081A2 (en) * | 2007-08-02 | 2009-02-05 | Actar Ab | Benzoind0l-2-one derivatives for use in therapy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2487159A1 (en) * | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
GB201207406D0 (en) * | 2012-04-27 | 2012-06-13 | Glaxo Group Ltd | Novel compounds |
CA2871534A1 (en) * | 2012-04-27 | 2013-10-31 | Glaxo Group Limited | Novel compounds |
-
2014
- 2014-12-24 CN CN201410821535.5A patent/CN104530014B/en active Active
- 2014-12-25 WO PCT/CN2014/094942 patent/WO2015096771A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2606716A1 (en) * | 1975-02-21 | 1976-09-02 | Ciba Geigy Ag | NEW DISPERSION COLORS |
CN1863785A (en) * | 2003-08-08 | 2006-11-15 | 沃泰克斯药物股份有限公司 | Compositions useful as inhibitors of voltage-gated sodium channels |
WO2009016081A2 (en) * | 2007-08-02 | 2009-02-05 | Actar Ab | Benzoind0l-2-one derivatives for use in therapy |
Non-Patent Citations (5)
Title |
---|
CAS RN:438488-85-8、438488-77-8、438479-43-7、438489-03-3;CAS;《STN Registry》;20020712 * |
CAS RN:62104-12-5、62155-54-8、62104-14-7;CAS;《STN Registry》;19841116 * |
Identification and Characterization of Novel Inhibitors of mPTPB, an Essential Virulent Phosphatase from Mycobacterium tuberculosis;Lan Chen et al.;《Medicinal Chemistry Letters》;20100707;第7卷(第1期);355-359 * |
Identification of Novel Compounds That Increase SMN Protein Levels Using an Improved SMN2 Reporter Cell Assay;Jonathan J. Cherrry et al.;《Journal of Biomolecular Screening》;20120430;第17卷(第4期);481-495 * |
Virtual screening, selection and development of a benzindolone structural scaffold for inhibition of lumazine synthase;Arindam Talukdar et al.;《Bioorganic & Medicinal Chemistry》;20100408;第18卷(第10期);3518-3534 * |
Also Published As
Publication number | Publication date |
---|---|
WO2015096771A1 (en) | 2015-07-02 |
CN104530014A (en) | 2015-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104530014B (en) | Sulfamide compound of the dihydrobenzo of 2 oxo 1,2 [cd] indoles 6 and combinations thereof and application | |
DE60203263T2 (en) | PYRAZOL DERIVATIVES AGAINST TGF OVEREXPRIMATION | |
CN105272904B (en) | N- phenylamide compound and its application | |
US20030096737A1 (en) | Caspase inhibitors and uses thereof | |
CA3057886A1 (en) | Bcl-2 inhibitors as apoptosis-inducing agents | |
RU2382029C2 (en) | Novel cyclohexane derivatives | |
BR112015027114B1 (en) | SELECTIVE HISTONE DEACETYLASE INHIBITOR COMPOUNDS AND THEIR USE | |
WO2013134298A1 (en) | Raf inhibitor compounds | |
CN103561576A (en) | Heterocyclic modulators of lipid synthesis | |
CN107669669A (en) | novel glucagon receptor antagonist | |
CN102816130B (en) | Thiazole compound and use thereof | |
TWI748996B (en) | Pyrimidine seven-membered ring compound, preparation method thereof, medicinal composition and application thereof | |
TW201522306A (en) | Heterocyclic derivatives and use thereof | |
PT2238110E (en) | 5.6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as antagonists for urotensine ii receptors | |
ES2782357T3 (en) | IRE 1 alpha inhibitors | |
TW200924758A (en) | Therapeutic agents | |
CN107001271A (en) | Hydroxyamidines analog derivative, its preparation method and its in application pharmaceutically | |
JP2021059578A (en) | Oxindole compounds and pharmaceutical compositions thereof | |
CN100491355C (en) | Cyclic diamine compound having five-membered cyclic group | |
Jae et al. | Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists | |
CN109134391A (en) | A kind of acyl sulfonamides analog derivative and the preparation method and application thereof | |
CN105968095B (en) | Indoles virtue sulfone derivatives and the preparation method and application thereof | |
JP2011519966A (en) | Novel N- (2-amino-phenyl) -acrylamide | |
DE60311861T2 (en) | PYRAZOLOCHINOLINE WITH IMMUNOMODULATING EFFECT | |
CN103951649B (en) | Heterocyclic substituted hydroxamic acid aromatic amides or its pharmaceutically acceptable salt, and its preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |